People

Patrick Johnson leads Dassault Systèmes’ corporate research and sciences, a responsibility held since2004, and joined its executive committee in2023. He joined as a software engineer in1996 and subsequently led its artificial-intelligence department, including knowledge-based engineering. His current research remit spans data science, biology, medicine, chemistry, physics and other sciences underlying AI-powered virtual twins. He is distinct from similarly named professionals outside this software company.

Philippe Laufer has led Dassault Systèmes’ global brands since2020 and customer-engagement teams since2021. He joined CATIA R&D in1985, worked on Boeing777 and automotive programs, led CATIA shape-design R&D from1996 and global R&D from2006, and became CATIA CEO in2012. He earned mechanical-engineering and production-automation qualifications from École Centrale de Nantes and ENSTA and holds a systems-engineering doctorate.

Florence Hu-Aubigny is Dassault Systèmes’ executive vice president for research and development, joining its executive committee in2020 to oversee development activities. She started at the company in1991, contributed to functional modeling,3DVIA and ENOVIA, and led development of the3DEXPERIENCE platform from2012. She studied at CESTI, subsequently renamed Supméca, and undertook postgraduate computer-aided-production-management studies.

Victoire de Margerie leads Dassault Systèmes’ corporate marketing, communication and identity and has served on the executive committee since2018. Her responsibilities include brand reputation, its3DEXPERIENCE Lab startup accelerator and public experiential spaces. She previously led international communications at Airbus. Her own biography identifies board roles at La Fondation Dassault Systèmes and Entreprises & Médias; these do not establish personal venture investments.

Grégory Abate has been Dassault Systèmes’ general secretary and an executive-committee member since2024, after joining as deputy general secretary in2023. His responsibilities include governance, public affairs, internal audit and controls. Earlier he served in France’s presidential and prime-ministerial offices, the Ministry of Finance and the European Commission. He studied at École des Mines, Sciences Po and ÉNA, earned a Sorbonne business-law master’s and worked as a Paris-bar lawyer.

Laurence Barthès is Dassault Systèmes’ executive vice president and chief people and information officer. She joined its R&D organization in1987 leading quality, processes and production engineering, became vice president for customer support and satisfaction in2002, then led information systems in2008 and took her combined people/information executive role in2009. Her remit combines workforce development and information systems.

Rouven Bergmann became Dassault Systèmes’ executive vice president and CFO inJanuary2022. He previously oversaw Medidata operations as its life-sciences chief operating officer, having joined Medidata as CFO in2015 and supported its2019 acquisition by Dassault Systèmes. Earlier he was CFO of SAP North America. He holds master’s degrees in mechanical engineering and business administration from the Technical University of Kaiserslautern and a doctorate in economics and finance from the University of Munich.

Elisa Prisner is executive vice president for strategy, industry, marketing and transformation. She joined Dassault Systèmes in2013 working on the Airbus account and A350 virtual-twin project, then led corporate transformation from2017. She joined the executive committee in2022, with expanded industry, marketing and sustainability responsibilities from2025. Earlier she consulted on aeronautical and systems engineering at Aeroconseil. Her education includes engineering at ECAM Rennes, an ENAC master’s and a jointly awarded aerospace-focused MBA.

Erik Swedberg has led Dassault Systèmes’ Americas organization as an executive-committee member since2020. He joined through the2006 MatrixOne acquisition, where he led business consultants, and later managed aerospace transformation projects and the global Boeing relationship. He became managing director for North America in2019. He studied aerospace engineering at the University of Minnesota.

Hubertus von Baumbach is chairman of Boehringer Ingelheim’s Shareholders’ Committee, effectiveJuly1,2025 and reaffirmed in the company’s September2026statement. He joinedBoehringer in2001, joineditsBoardofManagingDirectors in2009 and chairedthatboard from2016until2025. ShashankDeshpande succeededhim as executive-boardchair. The governance role is distinct from currentchiefexecutive or venturefundpartner.

Florence Verzelen leads Dassault Systèmes’ Europe, Middle East and Africa business and its Infrastructure & Cities sector. She joined the company and executive committee in2018, initially responsible for industry, marketing and education, and developed its sustainability function. Previously she held senior regional, operating and business-development roles at Engie. She is a graduate of École Polytechnique and Corps des Mines.

Harsha Deshmukh is a member of Boehringer Ingelheim’s Board of Managing Directors responsible for IT and Global Business Services. He joined the board effectiveFebruary1,2026 after technology leadership atInfineon, including chief information officer. His earlier work included enterprise IT, supply-chain management and industrial automation. He studied engineering inMumbai and management programmes atBabson andINSEAD.

Armin Wiesler is a member of Boehringer Ingelheim’s Board of Managing Directors responsible for Animal Health. He previously led regional businesses inSoutheastAsia,Korea,Australia andNewZealand and managed Thailand operations. Earlier experience includes marketing, corporate strategy and McKinsey. He earned economics degrees at the University of Freiburg.

Samson Khaou leads Dassault Systèmes’ Asia-Pacific business and joined its executive committee in2020. His responsibilities cover South Asia, China, South Korea, India and Japan. He joined the company’s R&D organization in1989 and later worked in CATIA/ENOVIA presales, product-lifecycle-management competency centers and major automotive projects. His role involves customer relationships and regional adoption of virtual-twin technology.

Frank Hübler is a member of Boehringer Ingelheim’s Board of Managing Directors responsible for Finance. His earlier work covered treasury, accounting, control and tax, UK/Ireland finance, regional financial management and internal audit. He studied business administration at the Catholic University of Eichstätt-Ingolstadt. Current board responsibility is distinguished from older corporate-finance timeline descriptions.

Pascal Daloz is Dassault Systèmes’ chairman and CEO, with the combined appointment effectiveFebruary21,2026. He became CEO in2024 after serving as deputy CEO in2023 and chief operating officer2020–2023; he joined the board in2020. His leadership has emphasized multidisciplinary technology, acquisitions, life sciences and healthcare. His own biography also identifies chair responsibilities at Medidata, Outscale and Centric PLM. This corporate executive identity does not establish a personal Click investment.

Paola Casarosa is a member of Boehringer Ingelheim’s Board of Managing Directors responsible for Innovation. Earlier responsibilities included CNS, retinal diseases, emerging therapeutic areas, prescription-pharma business development and respiratory licensing. She trained in molecular pharmacology at VUAmsterdam and pharmaceutical chemistry inTurin.

Michael Schmelmer is vice chairman of Boehringer Ingelheim’s Board of Managing Directors, responsible for Group Functions. He previously led Finance and Group Functions and founded the BI X digital innovation laboratory. Earlier roles included the company’s CIO and technology leadership at Infineon. His qualifications include aerospace/mechanical engineering and industrial engineering.

Shashank Deshpande chairs Boehringer Ingelheim’s Board of Managing Directors and leads its Human Pharma business. His chairman appointment took effect July1,2025. He joined the company in2012 and held commercial leadership roles inGermany and Japan, including Japan country managing director; he earlier worked at Sanofi in the United States and Capgemini. He studied business administration at the University of Hamburg. Current directory titles take precedence over older animal-health wording retained in regional career timelines.

Tahir Ropica serves as back office operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Vanessa Hartner serves as back office operations managerin at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Andreas Kinsinger serves as back office operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Ramin Shahnazary serves as senior back office operations manager & producer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Michael Weidemann serves as senior back office operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Robert Riedel serves as backoffice operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Leon Geurten serves as team lead back office operations at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Sara Kohl serves as office manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Leonardo Andreatta serves as office manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Henning Kircher serves as bilanzbuchhalter at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Alexander Haja serves as head of hr & office management at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Alexandra Dobre serves as office manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Maricel Toma serves as programmer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Vlad Ionescu serves as programmer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Christos Pazaras serves as senior web developer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Bogdan Schimbischi serves as programmer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Anna Schlei serves as team lead community building at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Lars Melberg serves as e-mail marketing manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Luisa Nelius serves as projekt managerin marketing at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Diar John serves as senior marketing managerin at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Sophie Schultheiss is published as Companisto Head of Marketing on parental leave. Her role remains source-qualified to that current directory status.

Till Wedemann is Companisto Senior Legal Counsel, working on equity financing, negotiations and portfolio transactions.

Daniel La Marca leads Companisto’s legal team, supporting financing transactions, investor interests and portfolio-company structuring.

Selma Özdemir serves as customer relations managerin at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Danae Fritsch serves as jr. customer relations managerin at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Janette Lenz serves as backoffice operations / office manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Marvin Brandt serves as onboarding manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Hajredin Xhaka serves as team lead customer relations at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Liliana Leybovich serves as senior operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Justus Müller is Companisto Investment Manager, supporting startup investments and financing. His published background includes venture-capital and investment work and developing financial structures.

Tim Weifenbach joined Companisto as Investment Manager in December2024. He brings experience in accelerator programmes, corporate innovation, digital health and investor relations, including co-founding a mental-health business.

Robin Ghosh is a Senior Investment Manager at Companisto, joining in October2023. His work includes startup assessment, diligence, negotiations and investor engagement. He previously spent ten years at the German Aerospace Center, supporting innovation and technology transfer.

Florian Huber is a Senior Investment Manager at Companisto, identifying and supporting companies especially in southern Germany. He joined in April2022 after postgraduate economics study focused on crowdinvesting.

Nicky Hughes is Companisto Investment Director. He develops deal flow, evaluates opportunities and structures financings, with experience across medtech, green technology and digital businesses.

Andreas Fakler is Companisto Investment Director, sourcing and supporting startups and representing the network on advisory boards including NIMMSTA. His earlier renewable-energy finance career included operations in California and North American expansion.

Sarah Buge is Companisto’s Chief Operating Officer. She oversees operations, organisational development, cross-team processes and execution of strategy, drawing on several years within the business.

Christoph Schweizer is Partner and Head of Investment at Companisto. He has more than two decades of venture-capital and business-angel financing experience, including a previous partnership at btov Partners.

Cristian Irimia is Companisto’s Partner and CTO. He develops the platform’s technical infrastructure, software frameworks, scalable systems and data architecture.

David Rhotert co-founded Companisto and serves as Managing Director and CEO. His entrepreneurial and legal background includes building partycard, corporate legal work and mergers and acquisitions. He participates in Berlin entrepreneurship and innovation organisations.

Tamo Zwinge co-founded Companisto with David Rhotert and serves as Managing Director. A lawyer with prior CMS experience, he leads legal structures and financing-model development. He studied law in Berlin and commercial law at Auckland and previously co-founded partycard.

Sean Marett advises ClavystBio. He served on BioNTech’s management board from2012 to2024, working on fundraising, commercial partnerships and expansion, and previously held commercial positions at Pfizer and GSK.

Ethan Jung Ryun Park is a ClavystBio director and a Temasek managing director. His background includes healthcare and life-sciences investing across Europe, the Middle East, Africa and Southeast Asia, following earlier work at SK Corporation.

Steve Krognes is a director of ClavystBio with senior finance and transaction experience in biotechnology. His previous positions include chief financial officer at Denali Therapeutics and Genentech and global mergers-and-acquisitions leadership at Roche.

Samantha Yeo manages finance and compliance at ClavystBio. She previously worked in KPMG’s governance, risk and advisory team, followed by finance and operational work supporting early-stage ventures at Lightstone Ventures.

Gladys Yeo is ClavystBio’s infrastructure manager and oversees the Node1 laboratories and offices. Her background includes diagnostic-laboratory operations and a biomedical science degree from Aston University.

Jamie Wong is ClavystBio’s finance director, responsible for financial systems, governance and support to portfolio companies. She previously held finance-director responsibilities at Temasek International.

Ewen Poh manages human resources at ClavystBio, covering recruitment, talent management and HR operations. She previously supported early-stage biotech businesses as an HR partner and worked in executive search.

Regis Ong leads infrastructure at ClavystBio, including its laboratory facility at Singapore Science Park. He previously served as technical head at Fuchs Singapore and helped establish Life Science Incubator.

Nge Hwee Ng is a founding-team member and business development and operations lead at ClavystBio. She previously worked in Temasek’s Portfolio Development Group and in corporate finance and valuations at PwC.

Jason Ng is ClavystBio’s legal lead, advising its venture-building and investment activities. His career includes Singapore’s Ministry of Law and private- and social-sector legal work, with extensive experience supporting startups and transactions.

Vincent Lai is vice president for cybersecurity and IT at ClavystBio. His responsibilities cover information security, digital infrastructure and data governance, drawing on experience in IT, privacy and regulated business environments.

Grace Chua manages community engagement at ClavystBio, organizing life-sciences events and connections. She previously developed partnerships and youth programmes at Singapore’s National Environment Agency.

Carol Chan is ClavystBio’s executive assistant and office manager. She supports executive schedules and office operations, following administrative work with Eric Salmon & Partners and DTCA executive-search businesses.

Marcus Tan is a senior associate at ClavystBio. He previously managed Danaher’s Asian venture activity in genomic medicine, bioprocessing and diagnostics, and worked on investments at Heritas Capital.

Ning Mao is a senior associate at ClavystBio focused on investment and venture creation. Earlier work includes early-stage biotech investing, portfolio-company operations and business development, and consulting for life-sciences clients.

Charles Yiliu Zhang is an assistant vice president in ClavystBio’s therapeutics team. His background combines biotech venture investing, patent work and postdoctoral research at A*STAR’s Institute of Molecular and Cell Biology. He earned a cell and molecular biology doctorate at NUS.

Cheryl Tan is an assistant vice president for medtech at ClavystBio. She brings clinical experience to healthcare investment evaluation and previously worked with Temasek’s life-sciences investment team.

Johnny Ng is an assistant vice president in ClavystBio’s therapeutics team. He previously worked on life-sciences investments at Xora Innovation and led a discovery programme at Singapore’s Experimental Drug Development Centre.

Yingmin Wang is a medtech director at ClavystBio. Her career spans research at A*STAR, venture and business development at Singapore’s Economic Development Board, and leadership of Applied Materials’ Southeast Asian regional and technology offices.

Yvonne Koh is a therapeutics director at ClavystBio. Her background includes early-stage venture diligence and programme management at Lightstone Ventures and innovation-policy work as a deputy director at Singapore’s National Research Foundation.

Anselm Tan leads medtech at ClavystBio, including digital-health ventures. He formerly headed venture capital at Heritas Capital and launched Asia-Pacific health-technology investments as a partner at Philips Ventures.

Wen Qi Ho leads therapeutics at ClavystBio, investing in and building healthcare companies. She previously led Lightstone Ventures’ Singapore investment and operating activities, covering biotechnology and medical devices.

Kang Lin Ong is chief financial officer of ClavystBio. His earlier finance leadership includes Luye Medical Group and Docquity. He holds a finance doctorate from EDHEC, a Wharton MBA and CFA qualification.

Khoo Shih is ClavystBio’s chief executive and a founding-team member. She previously led life-sciences investing at Temasek and worked in venture investment at UOB Venture Management. Her scientific training includes a genetics and development doctorate from UT Southwestern.

Analyst working on leveraged-buyout and venture-capital transactions.

Investment professional with experience in healthcare and automotive business analysis and training in law and management.

Academic and business adviser with experience in investment, management and social-impact projects; no precise AVM job title is stated on the published roster.

Investment-team associate with a finance and strategic business-analysis background.

Supports operational processes and control activities, following consulting work.

Advises on business development, international expansion and transformation, drawing on supply-chain and logistics experience.

Investment and strategy professional whose background includes consulting, financial institutions and entrepreneurial ventures; no precise AVM job title is stated on the published roster.

Sources and assesses investment opportunities, with prior strategy-consulting and corporate-law experience.

Investment and operating professional with experience in industrial restructuring, mergers and acquisitions.

Operating executive and investor with extensive experience building international clinical-services businesses.

Private-equity and accounting professional with transaction, audit and corporate-governance experience.

Oversees AVM operations and selected portfolio-company activities.

Private-equity investor with an operating, finance and business-management background who co-founded AVM with Giovanna Dossena.

Leads people, workplace and culture activities and supports the firm’s internal operations.

Supports investor communications, reporting and registry relationships, following fund-operations work at Automic Group.

Oversees fund accounting, reporting, investment administration, audit and tax compliance, following audit work at PwC and EY.

Evaluates private-equity opportunities and monitors portfolio investments, following work at Carlyle in London and PwC.

Sources, evaluates and executes private-equity investments and helps structure fund solutions for Australian and international investors.

Leads investment-team activities across primary funds, co-investments and secondaries, with prior private-equity experience in Australia and the United Kingdom.

Former PwC financial-services partner with investment-management, assurance, transaction and governance experience.

Experienced Australian company director and legal adviser, formerly chief executive of Sydney’s successful Olympic bid.

Private-equity investor and fund manager who co-founded Odyssey Private Equity and previously held leadership roles at CHAMP Ventures, Pollination and the Australian Investment Council.

Founded Vantage in 2004 and oversees its private equity investment programs, following development-capital and private-equity work at St George Bank.

Published name: Bobby Napiltonia. Adviser to Verix (Virtualness). Existing same-name identities are preserved; no identity merge is asserted without corroboration.

Published name: Namrata Ganatra. Adviser to Verix (Virtualness). Existing same-name identities are preserved; no identity merge is asserted without corroboration.

Published name: Ben Yu. Adviser to Verix (Virtualness). Existing same-name identities are preserved; no identity merge is asserted without corroboration.

Named VP US in the company’s management-photo caption. The same photo was uploaded September 1, 2026 and appears on the current About page. The company’s July 2022 announcement describes her recruitment from Harvard’s Office for Technology Development.

Named CFO in the company’s management-photo caption. The same photo was uploaded September 1, 2026 and appears on the current About page; the caption is on an older article and no appointment date is asserted.

Named CBO in the company’s management-photo caption. The same photo was uploaded September 1, 2026 and appears on the current About page; its explanatory caption is on an older financing article, so the precise appointment date is unknown.

Maastricht University professor and MERLN Institute management member, named on UpNano’s scientific advisory board.

Optics and electronics researcher identified by UpNano with A*STAR IMRE and Singapore’s National Semiconductor Translation and Innovation Centre.

Additive manufacturing researcher identified by UpNano as Director of the Center of Additive Manufacturing and Design Innovation at the University of Texas.

Professor at the Wake Forest Institute for Regenerative Medicine, named on UpNano’s advisory board.

Cell and tissue research specialist named on UpNano’s scientific advisory board.

Professor at TU Wien and head of its 3D Printing and Biofabrication research group. The company names him as a founder and scientific adviser.

Co-founder responsible for operations, named in UpNano’s founding-team description.

Co-founder responsible for technology, named in UpNano’s founding-team description.

Co-founder and chief executive of UpNano, named on its current company page.

IT professional with software-consulting and SAP Business One experience. This staff role comes from a dated company interview; continued appointment in October 2026 is not independently confirmed.

Software developer with a business information technology degree and game-development experience. The company interview describes joining Taika3D in 2018; continued appointment in October 2026 is not independently confirmed.

Industrial designer and orthotics/prosthetics CAD specialist. This staff role is published in a dated company interview; continued appointment in October 2026 is not independently confirmed.

Marketing and communications professional with experience in orthopedic and aesthetic medical devices and international trade.

Technology entrepreneur with experience in electronic circuit design, industrial 3D imaging and automated CAD software.

Works on systems architecture, design for manufacturing and the standard product platform. His company biography describes digital manufacturing of medical devices and a visiting professorship at Newcastle University.

Production technology and product development specialist involved in establishing Taika3D’s design-automation platform.

Software developer and team leader working on 3D design solutions; previously worked in electroluminescent-display product development.

Orthotics industry executive whose company biography describes clinical sales teams, custom manufacturing and NHS experience.

Registered management-board member of ARIS Occitanie. AD’OCC’s official 2022 activity report also identifies him as the regional economic-development agency’s director general; that external role is source-dated.

Registered management-board member of ARIS Occitanie. ARAC Occitanie’s published organizational sources identify him as its director general, providing regional infrastructure and development experience.

Named by ARIS’s latest mission report as a permanent decision-committee representative from APRC. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Bpifrance. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Bpifrance. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from CCI Occitanie. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Nubbo. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Magellim. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Groupama d’Oc. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Captain Watt. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Caisse d’Épargne Languedoc-Roussillon. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Caisse d’Épargne Midi-Pyrénées. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Banque des Territoires. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from AREC. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from ARAC. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Région Occitanie. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from AD’OCC. This affiliation is documented in the 2025 report published in July 2026.

Investment analyst supporting ARIS through its external operator OCCTE. ARIS’s latest mission report names her in the investment team and states that the analyst joined in early 2026; further career history is not publicly established in that source.

Administrative and financial director at ARIS since February 2023. Previously managed real-estate fund finances at Midi 2i and worked on financial management for Crédit Agricole Services Immobiliers. Holds a accounting, control and audit degree from Toulouse School of Management. OCCTE’s current team also names him administrative and financial director.

Head of Investments at ARIS Occitanie, serving in the investment team provided by external operator OCCTE. The latest mission report describes the investment-management hire in 2025.

Director of ARIS since February 2023, with experience in regional innovation, sustainable development and technology businesses. Previously worked in audit at PwC and transaction services at KPMG, co-led a connected-vehicle software company, and managed innovation programs at Toulouse Métropole. Holds a finance and audit degree from Paris Dauphine. OCCTE’s current team names him managing director and chief compliance and internal control officer (RCCI).

Chair of ARIS Occitanie’s supervisory board, responsible for strategic oversight of the regional investment company.

President of ARIS Occitanie’s management board, overseeing the regional investment company’s strategy and investment decisions. OCCTE’s current team names him president and chairman. Its professional biography describes experience in energy-transition investing, territorial development and public-private partnerships, including prior SHEM-Engie and Compagnie Nationale du Rhône roles.

Charles Wiebe is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Kara Walker is published by University of Vermont Health as Board Secretary. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Betsy Vicencio is published by University of Vermont Health as Board Vice Chair, Chair of Compensation Committee and Chair, Audit & Risk Management Committee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Christine Peters is published by University of Vermont Health as Chair, Strategic Planning Committee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Richard Page is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Heidi Melbostad is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Robert Main, Jr. is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Dain LaRoche is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Kevin Hart is published by University of Vermont Health as Trustee. A retired Alice Hyde Medical Center executive with procurement, facilities and support-services experience; retired in2015 after three decades there. He is distinct from the existing same-name Curie.Bio strategic-finance professional and the entertainer.

Sarah Harm is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Erica Metzger Hare is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Tom Golonka is published by University of Vermont Health as Board Chair and Chair, Governance Committee. Thomas J. (Tom) Golonka is an investment-management professional and CFA/CFP charterholder; the health-system board biography describes work at Silverlake Wealth Management and Vermont pension governance.

Kim Farnham is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Dominic Eisinger is published by University of Vermont Health as Chair, Investment Committee. A biotechnology executive and entrepreneur with protein-biomarker testing and clinical-development experience; chairs the system’s Investment Committee. The own board biography names historical company roles, which are not separately asserted as current jobs.

John Dwyer is published by University of Vermont Health as Chair, Finance Committee. A credit-union executive and accountant, published as president and CEO of EastRise Credit Union. His university-health role is finance-committee governance rather than a personal portfolio check.

Victoria Duley is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Joseph Donnery is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Steven Cacchio is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Jesse Bridges is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Dragos Banu is published by University of Vermont Health as Chair, Quality & High Value Care Committee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Judy Schaechter is published by University of Vermont Health as Chief of Pediatrics, Golisano Children’s Hospital. A pediatrician and academic leader, previously at CDC, the American Board of Pediatrics and University of Miami; began the UVM pediatrics chair role July1,2026.

Joseph Pierson is published by University of Vermont Health as Chair, Department of Dermatology. A dermatologist and educator with previous U.S. Army medical leadership and active-duty service.

Jeffrey Peipert is published by University of Vermont Health as Chair, Department of Obstetrics, Gynecology, and Reproductive Sciences. A physician-scientist and academic specializing in reproductive health, obstetrics and gynecology.

Mitchell Norotsky is published by University of Vermont Health as Chair, Department of Surgery. A cardiothoracic surgeon and academic experienced in complex coronary, pulmonary and thoracic surgical care.

Claude Nichols is published by University of Vermont Health as Chair, Department of Orthopedics and Rehabilitation. An orthopedic surgeon whose specialty includes sports medicine, knee and shoulder surgery, and traumatic injuries.

Shalina Nair is published by University of Vermont Health as Chair, Department of Family Medicine. A family physician and academic interested in prevention, chronic disease, eConsults and operational quality improvement.

Nataniel Lester-Coll is published by University of Vermont Health as Chair, Radiation Oncology. A radiation oncologist and clinical-trial researcher treating genitourinary cancers and tumors of the brain and central nervous system.

Andrew Goodwin is published by University of Vermont Health as Interim Chair, Department of Pathology and Laboratory Medicine. A clinical pathology academic and medical director working on thrombosis and hemostasis; department chair appointment is explicitly interim.

Anne Dixon is published by University of Vermont Health as Chair, Department of Medicine. A physician-scientist researching asthma and pulmonary disease associated with obesity and metabolic dysfunction.

Kristen DeStigter is published by University of Vermont Health as Chair, Department of Radiology. A radiologist researching sustainable and affordable diagnostic imaging in rural and resource-constrained settings.

Peter Calabresi is published by University of Vermont Health as Chair, Department of Neurological Sciences. A neurologist and multiple-sclerosis researcher whose work concerns precision medicine and neuroimmunology.

Richard Bounds is published by University of Vermont Health as Interim Chair, Department of Emergency Medicine. An emergency physician and educator who helped establish Vermont’s emergency-medicine residency; current chair title is explicitly interim.

Rebecca Aslakson is published by University of Vermont Health as Chair, Department of Anesthesiology. A critical-care anesthesiologist and palliative-care physician-scientist researching patient- and family-centered care.

Robert Althoff is published by University of Vermont Health as Chair, Department of Psychiatry. A child and adolescent psychiatrist researching emotional self-regulation, also a Larner College of Medicine academic.

Marc Kosak is published by University of Vermont Health as President & Chief Operating Officer (Central Vermont Medical Center). A hospital operations executive previously at Greenwich Hospital and Yale New Haven Health.

Christine Werneke is published by University of Vermont Health as President & Chief Operating Officer (Home Health & Hospice). A community and population-health leader who became Home Health & Hospice president and COO in2023.

Bob Ortmyer is published by University of Vermont Health as President & Chief Operating Officer (Elizabethtown Community Hospital Porter Medical Center). A hospital executive with a long WellSpan career; joined Elizabethtown in2021 and also took on Porter leadership inMay2024.

Michelle LeBeau is published by University of Vermont Health as President & Chief Operating Officer (Champlain Valley Physicians Hospital Alice Hyde Medical Center). A health-care leader with a nursing background, leading Champlain Valley Physicians Hospital and Alice Hyde Medical Center.

Stephen Leffler is published by University of Vermont Health as Chief Executive Officer, UVM Health; President & Chief Operating Officer, UVM Medical Center. An emergency physician and medical educator with more than thirty years at the medical center. Appointed permanent system CEO January2026 after interim service fromOctober2025; older SunilEappen CEO listings are superseded.

Jessica Moschella is published by University of Vermont Health as Senior Vice President, High Value Care, UVM Health. The health-system executive responsible for its High Value Care portfolio; this operating leadership position is not venture-fund management.

Eric Miller is published by University of Vermont Health as Senior Vice President, General Counsel, UVM Health. The system’s senior legal executive. His UVM identity is distinct from the existing same-name Arizona Tech Investors professional; no unrelated investment roles or images are merged.

Ginger Lubkowitz is published by University of Vermont Health as Chief Development Officer of Academic Health Sciences, UVM Health & UVM Foundation. The health-system directory identifies a joint Academic Health Sciences development role involving UVM Health and the separate UVM Foundation. Its card contains apparently mismatched biographical text, which is not copied or treated as this individual’s education.

Brad Krompf is published by University of Vermont Health as Executive Director, UVM Health Medical Group. A health-care operations leader experienced in consulting, ambulatory surgery and multidisciplinary clinical services.

Carrie Howard-Canning is published by University of Vermont Health as Senior Vice President, Chief Nursing Executive, UVM Health. A nurse and senior nursing executive whose background includes decades of clinical and leadership work across several UVM hospitals.

Mary Broadworth is published by University of Vermont Health as Chief Human Resources Officer, UVM Health. A human-resources executive with experience in organizational transformation, integration and process improvement; joined the medical center in2020 and led system HR transformation from2023.

Richard Vincent is published by University of Vermont Health as Executive Vice President, Chief Financial Officer, UVM Health. A finance executive with more than three decades at the health system, overseeing integration of financial and administrative operations. The FY2023 tax filing also identifies him in venture-subsidiary governance; it does not disclose a personal Cilcare check.

Ramsey Herrington is published by University of Vermont Health as Chief Physician Executive of UVM Health; President and CEO, UVM Health Medical Group. An emergency physician and medical educator who helped establish the system’s emergency-medicine residency and academic department.

Edward Hu is a director/member of 6 Dimensions Capital Limited in its March2026 legal filing. The WuXi-hosted June2023 BOLD event supplies his authentic portrait and then-current vice-chairman affiliation; that event title is historical.

WuXi AppTec founder Ge Li was identified as founder and chairman in 6 Dimensions’ December2017 close announcement and remains a legal director/member in its March2026 filing. This person is distinct from the Swinburne communications researcher of the same name. WuXi AppTec current published biography: Scientist and entrepreneur leading the company since2000, pioneering its integrated open-access drug research/development/manufacturing platform. Organic chemistry PhD from Columbia University and chemistry degree from Peking University. Current own director filing identifies chair and CEO. Existing 6Dimensions role and authentic portrait preserved.

Xiaoliang Sunney Xie is published by 6 Dimensions Capital as Adviser (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The card’s external institutional title belongs to the adviser’s outside organization, not a 6 Dimensions executive office.

Quanlu Zheng is published by 6 Dimensions Capital as Adviser (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The card’s external institutional title belongs to the adviser’s outside organization, not a 6 Dimensions executive office.

Jason Sun is published by 6 Dimensions Capital as Adviser (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The card’s external institutional title belongs to the adviser’s outside organization, not a 6 Dimensions executive office.

Allen Chao is published by 6 Dimensions Capital as Adviser (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The card’s external institutional title belongs to the adviser’s outside organization, not a 6 Dimensions executive office.

Ching Zhu is published by 6 Dimensions Capital as Affiliate Member (undated published roster); Director and Member, Qingsheng Zhu (March2026 filing). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Wei Li is published by 6 Dimensions Capital as Affiliate Member (undated published roster); Director and Member (March2026 filing). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Norman Chen is published by 6 Dimensions Capital as Venture Partner (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Dong Wu is published by 6 Dimensions Capital as Venture Partner (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Hongye Sun is published by 6 Dimensions Capital as Venture Partner (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Richard Li is published by 6 Dimensions Capital as Legal Director. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Vivian Li is published by 6 Dimensions Capital as Finance-VP. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Jin Wang is published by 6 Dimensions Capital as VP Finance. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Deep experience in VC/PE finance area, served various cross border venture funds Ex-Senior Manager at Standish Management Ex-Audit Manager from Deloitte, specialized in Investment Company industry

Christina Chung is published by 6 Dimensions Capital as Chief Financial Officer. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Based in Hong Kong, Ms. Christina Chung is the Chief Financial Officer of Frontline BioVentures. Christina has over 13 years of hands-on professional experience in the finance and accounting field. Prior to Frontline BioVentures, Christina was the Associate Director of Fidelity Growth Partners Asia (Fidelity) between 2009 to 2013, responsible for the finance reporting, valuation and portfolio management activities.

Jia Sun is published by 6 Dimensions Capital as Associate. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Leo Yan is published by 6 Dimensions Capital as Senior Associate. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Mr. Leo Yan joined Frontline BioVentures in 2016 with over 5 years of investment experience in healthcare industry. Before joining Frontline BioVentures, Mr. Yan was Senior Investment Manager of Global Healthcare Service Team in Fosun Health Holdings, a department under Fosun International (00656.HK).

Corrine Chen is published by 6 Dimensions Capital as Vice President. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ms. Corrine Chen joined Frontline BioVentures in 2017 with over 5 years of investment and professional service experience. Ms. Chen started her career in KPMG, leading and participating in several annual audit engagements of China and HK listed companies, and several NASDAQ/NYSE/HKEX IPO audit engagements as an Assistant Manager in audit department.

Jie Zhang is published by 6 Dimensions Capital as Vice President. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ex-Principal Scientist, Infectious Disease Research, WuXi AppTec Ex-Institute Pasteur, CNRS France MS in systemic biology in University of Paris PhD in Pathology and Cell Biology from University of Montreal

Jianwei Yuan is published by 6 Dimensions Capital as Vice President. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ex-Senior Investment Manager for Medical Device M&A at Fosun Pharma Ex-Scientist, Pharmaceutical R&D in CNS at Glaxo Smith Kline MS from Shanghai Institute of Biological Sciences, MBA from Fudan University, CFA Level I

Wei Zhao is published by 6 Dimensions Capital as Executive Director. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ex-Senior Life Sciences Specialist, L.E.K. Consulting Postdoctoral fellow, Massachusetts Eye and Ear Infirmary / Harvard Medical School PhD in Neuroscience, Northwestern University

Hannes Smárason is published by 6 Dimensions Capital as Senior Managing Director. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Colin Wang is published by 6 Dimensions Capital as Partner. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Qin Xie is published by 6 Dimensions Capital as Partner. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The own website publishes Qin Xie as Partner and also retains an older Executive Director card. Its older HTML interleaves another person’s qualifications; those qualifications are not attributed to Qin.

Rebecca Zhu is published by 6 Dimensions Capital as Partner. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ms. Zhu joined Frontline BioVentures in 2014 with over 6 years of investment experience in healthcare industry. Prior to Frontline BioVentures, Ms. Zhu was Analyst of Power Pacific Corporation (member of Power Corporation of Canada), specializing in research and investment in publicly traded healthcare companies listed in Shanghai, Shenzhen and Hong Kong Stock Exchange.

Erdong Hua is published by 6 Dimensions Capital as Partner. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Mr. Hua is a Partner of Frontline BioVentures. He joined the team in 2012 with over 10 years of dedicated experience in medical/healthcare, venture capital investment and financial industries.

Leon Chen is published by 6 Dimensions Capital as CEO & Founding Partner; Director and Member (March2026 filing). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Dr. Chen is Founder and Managing Partner of Frontline BioVentures. Leon has over 20 years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor.

Chief executive of Kona Venture Partners LLC, as named in the Korean Venture Capital Association’s current English firm directory. Korean name: 최화진. Also rendered Hwa-Jin Choi.

Ojasvi Yadav previously built AI models, pipelines and product software at Sabi. His current personal site identifies independent work on The Learning Harness, following AI leadership at Writesonic and Dukaan and research at V-SENSE.

Abhyuday Hari Prasad joined Sabi as a software engineer in 2026. His firstperson announcement identifies its Palo Alto brain-computer-interface work and founders Rahul Chhabra and Atmadeep Banerjee. He studied engineering at Dayananda Sagar College and participated in IASNLP2026 language-processing research.

Guruprasad Kudte appears in Sabi’s published launch research-team roster; exact operating title is unpublished.

Varsha V. is publicly identified with Sabi in Bengaluru and its launch research-team roster.

Sameeha Maheen appears in Sabi’s published Bengaluru launch research-team roster; exact operating title is unpublished.

Bhavya L is a publicly named Sabi researcher with an interest in neural decoding.

Mohammed Raasith is publicly identified with Sabi’s Bengaluru research team and cognitive-neuroscience research.

Ritika Khanna works with Sabi; her professional biography describes computational neuroscience, EEG processing and AI.

Vidyun Mittal is a publicly named Sabi researcher with neuroscience and biomedical research experience.

Hervé Jean Lemaitre is the legally published president of Sud PME Croissance, the Montpellier direct investment company registered as SIREN512778465. The company’s formation notice and its certified April2022 decisions name him in that capacity. This affiliation is supported by legal filings; a broader career biography and an authentic individual portrait have not been established. He is not identified with the similarly named neuroscience researcher or other unrelated namesakes.

Eddu Israel is identified as Sabi’s data analyst lead in its public launch-team announcement.

Abhinit Ranjan heads Sabi operations and published its April2026 launch announcement.

Bhavya Mandali was featured by Virtual Therapeutics in its March29,2024 Celebrating Women in Tech employee interview as a VR software engineer. She describes studying computer engineering, pursuing a master’s degree after discovering virtual reality, and combining software engineering with creative work. She reported about ten years in the software industry and discussed returning to engineering after parenting-related career breaks. The own article publishes her original portrait. Her role is source-qualified as reported in2024 rather than assumed current employment.

Marissa Bertorelli was named a director of Virtual Therapeutics Corporation in its May31,2024 primary SEC tender roster. At that time she was a Polaris Partners principal, having joined in2019, focused on healthcare investing. Prior to Polaris she traded equity derivatives in Goldman Sachs’ Securities Division. She holds an MBA from Stanford, where she was an Arbuckle Fellow, and BS in Finance from Boston College. Her2024 conference-organizer biography corroborates her Polaris career and publishes an authentic portrait. This is a last-confirmed2024 parent board appointment; no current Polaris employment or complete2026 parent board is asserted.

Ben Wiegand, PhD, was an independent director of Virtual Therapeutics Corporation in its May31,2024 primary legal roster. That filing identifies him as Lore Health Chief Scientific Officer sinceJune2023 and a founding partner of Connected World Without Disease Accelerator since2022, following Optum Labs SVP R&D2020–2022 and25years of increasingly senior Johnson & Johnson roles. Those included Janssen global leadership of World Without Disease Accelerator2017–2020 and Disease Interception Accelerator2014–2017. He has a chemistry undergraduate degree from the University of Illinois and MA/PhD in Physical Chemistry from Harvard. The SEC calls his undergraduate degree BA while an earlier J&J biography calls it BS; the degree field is retained without resolving that conflict. Current parent board service and an authentic original portrait are not verified.

Patrick Tan is a data scientist at Click Therapeutics. His own company feature describes collaboration with machine-learning, data-engineering, software and clinical-development teams to analyze user behavior and support therapeutic development. He is distinct from the epigenomics researcher and Auristone co-founder of the same name.

Gosia Machniewska is an associate design director at Click Therapeutics. Her company-published employee feature describes designing the cognitive-restructuring experience within a digital therapeutic, with the goal of making difficult treatment activities easier for patients to engage with.

Ioana Medrea, MD, is a scientific advisor to Click Therapeutics and a headache specialist. The University of Toronto states that she joined its Centre for Headache in September 2024 from SUNY Upstate; the Click advisory page’s SUNY affiliation is therefore historical.

Jihan Grant, MD, is a scientific advisor to Click Therapeutics and a headache specialist at Mount Sinai. Her institutional biography describes neurology, headache medicine and interventional pain training and leadership of its headache-treatment and translational-research center.

Merle Diamond, MD, is a headache-medicine specialist and scientific advisor to Click Therapeutics. Her clinical institution now publishes her at Endeavor Health Diamond Headache & Migraine Center; the older Click biography’s independent clinic title is treated as historical.

Stewart Tepper, MD, FAHS, is a scientific advisor to Click Therapeutics. He is a headache-medicine specialist whose published research and educational work includes migraine, headache therapies and neuromodulation.

Joseph Kvedar, MD, called Joe Kvedar on Click Therapeutics’ advisory page, works in connected health and dermatology. He advises Click scientifically, and his published academic work examines how digital tools can support healthcare delivery and patient engagement.

Andrea Leonard-Segal, MD, is a scientific advisor to Click Therapeutics. Its biography describes medical practice, regulatory consulting and prior FDA drug-review experience. External career entries are attributed to that source rather than treated as a separately audited current employer directory.

Bruce Leuchter, MD, co-founded Neurvati Neurosciences and GRIN Therapeutics and became Neurvati president, CEO and board member in September2021. A neuropsychiatrist, he trained at New York Presbyterian/Weill Cornell and earlier worked in clinical neuropsychiatry and healthcare finance at Goldman Sachs, Credit Suisse and PJT. He also co-founded Click Therapeutics as its founding neuropsychiatrist, a source-published advisory affiliation distinct from its current executive team. His own Neurvati biography establishes current leadership; older Click external-career entries are historical.

Joshua Steinerman, MD, is listed by Click Therapeutics as its founding neuroscientist within the advisory directory. His published career includes neuropsychiatry and clinical development at GW, Jazz and Teva, and academic neurology. This designation does not establish a current full-time employment position.

Brian Iacoviello, PhD, is a scientific advisor to Click Therapeutics. His work concerns cognitive biases in depression and anxiety and their treatment using cognitive and behavioral approaches. The company’s biography records his psychiatry research affiliation with Mount Sinai.

Barry Fine, MD, PhD, is a scientific advisor to Click Therapeutics and a physician-scientist at Columbia. His research uses stem cells and engineered heart tissue to study molecular cardiology and potential drug and gene therapies.

Nicholas Schork, PhD, advises Click Therapeutics scientifically. His research concerns quantitative medicine, genomics and individual differences in treatment response. Company and XPRIZE biographies record his work at the Translational Genomics Research Institute; he also appears as a historical Click director in early issuer filings.

Douglas Langa, called Doug Langa in Click Therapeutics’ directory, serves on its board. His published biography describes senior leadership at Novo Nordisk and earlier pharmaceutical experience. Click’s October 2026 SEC filing states that he was elected after the April 7, 2026 first sale.

Alex Zisson is a healthcare investor whose historical managing-director role at H.I.G. BioHealth Partners is documented in Click’s2021financing announcement. Orbus Therapeutics’ own board biography describes him as a HealthBridge managing director and records earlier healthcare investing at ThomasMcNerney and equity research at HambrechtQuist and its successors. He graduated from Brown University. The current HealthBridge manager directory does not list him, so continuation of that manager position is qualified rather than inferred. His October2026Click director status is sourced and managed separately. The portrait is an authentic named H.I.G. publisher photograph.

Bruce Robertson has investment experience at H.I.G. BioHealth and Toucan Capital. Click’s website still lists him as a board member, but its October 1, 2026 SEC filing explicitly says he was elected after the April 7 financing and resigned before that filing. His current H.I.G. HealthBridge title is Senior Advisor; the older Click biography’s managing-director title is historical.

Rick Rosen is co-president of H.I.G. Capital and shares day-to-day oversight and fund investment-committee responsibilities with Douglas Berman. He joined H.I.G. in1998 after work at General Electric and GECapital. He studied economics at Stanford and earned a Harvard MBA. The HealthBridge affiliation is shared-platform governance.

Cleantech and industrial investor with earlier roles at SINTEF, the Research Council of Norway and Yara.

Entrepreneur with startup experience in Silicon Valley and Europe and former CEO of student accelerator Insj UiO.

Corporate venture investor and startup founder with experience establishing venture units and serving on company boards.

Serial technology entrepreneur who helped found Kantega and Signicat and previously led technology investing at Investinor.

SaaS revenue executive with previous leadership roles at Uniphore, Boost.ai and Zuora.

AI executive and former Boost.ai COO with experience scaling software companies internationally.

Stanford neurosurgery department chair specializing in brain tumors, trigeminal neuralgia and neurological cancer immunotherapy.

Mount Sinai neurosurgeon and professor specializing in brain tumors, image-guided surgery and translational gene and stem-cell research.

Pharmaceutical-development specialist and Synthon founding partner with experience in regulatory strategy, manufacturing, quality and commercialization.

Life-sciences investor and company builder with more than 30 years in technology commercialization, business development and M&A.

Douglas Berman is co-president of H.I.G. Capital, published as shared executive management on the HealthBridge site. He joined H.I.G. in1996 and previously worked at Bain. His education includes economics at the University of Virginia and an MBA from Wharton. The current capacity is parent-platform oversight rather than a claimed separate GP directorship of every fund.

Anthony Costello is a Click Therapeutics board member and is identified by the company as CEO of Medidata. His earlier career includes Medidata Patient Cloud and Mytrus. Click’s 2025 SEC filing states that he joined the board in connection with that financing.

Brian Schwartz is H.I.G. Capital’s CEO and a member of its executive committee, providing strategic direction across its global investment strategies including HealthBridge. He joined H.I.G. in1994 and previously spent six years as co-president. Earlier roles included PepsiCo strategy and DillonRead investment banking. He holds University of Pennsylvania and Harvard Business School degrees.

Jeffrey Berkowitz is a Click Therapeutics board member. His company biography identifies leadership at Real Endpoints and prior executive experience at UnitedHealth Group and Walgreens. The October 2026 SEC filing confirms his issuer director role.

Tony Tamer is a founder and executive chairman of H.I.G. Capital, named in HealthBridge’s shared parent-management directory. He previously was a Bain partner and works with early-stage and middle-market companies. He studied at Rutgers, Stanford and Harvard Business School. The affiliation does not establish a personal check into every strategy portfolio company.

Sami Mnaymneh is a founder and executive chairman of H.I.G. Capital, published in HealthBridge’s shared executive-management directory. He led the firm as CEO from its1993inception until2026. Previously he was a Blackstone managing director and worked at Morgan Stanley. He studied at Columbia and earned Harvard law and business degrees. This is shared platform governance, not separately asserted employment by every HealthBridge LP.

Maria Forero is an Accelmed senior advisor and serves on Click Therapeutics’ board. Her work spans healthcare operations, investing and business development. She founded and managed Ridgetop Health Fund and previously held leadership roles at Novartis and healthcare investment-banking responsibilities at Morgan Stanley. Her studies include human genetics and public health.

Muzammil Mansuri, PhD, chairs Click Therapeutics’ board. The company’s published biography records venture work at F-Prime Capital and prior executive roles at Sanofi, Gilead and industry biotechnology companies. Those external career entries are source-published history rather than a separately verified current employer roster.

Viveca Livezey, MD, FAAN, is chief medical advisor at Click Therapeutics. She contributes neurological and medical expertise to its development of digital therapeutics; the company publishes her named biography and portrait.

Ritesh Manchanda heads engineering at Click Therapeutics, according to its current company directory. A named authentic portrait is published; further career or educational details are not established by this source.

Daniel Rimm, also called Dan Rimm in the company’s employee feature, heads product at Click Therapeutics. His published account emphasizes collaboration across clinical, technology and science teams in designing software-based treatments.

Cassandra Snipes, PhD, is head of science at Click Therapeutics, according to its current leadership directory. The source publishes an authentic named portrait but no detailed career biography; additional education and prior employers are not assumed.

Sarah Jackson leads business development and alliance management at Click Therapeutics. Her work concerns the company’s pharmaceutical collaborations and commercial partnerships; earlier company announcements also identified her as chief of staff.

Tarique Collins is chief legal officer at Click Therapeutics. A lawyer with privacy and information-management credentials, he oversees the company’s legal function in the development of digital medicines.

Rich DeNunzio, also identified as Richard DeNunzio in company releases, leads commercial strategy at Click Therapeutics as chief commercial officer. The company publishes a named biography and authentic portrait.

Austin Speier is chief strategy officer at Click Therapeutics. His published work includes corporate strategy, scientific development and digital medicine; his current role is confirmed by the company’s own leadership directory.

Randall Stanicky is chief financial officer of Click Therapeutics. He previously covered healthcare as an equity analyst at RBC Capital Markets and Goldman Sachs, including research into digital health. His published board experience includes the Children’s Tumor Foundation and TherapeuticsMD.

David Benshoof Klein founded Click Therapeutics in 2012 and is its chief executive officer and a board member. His work spans software-based medical treatments, healthcare entrepreneurship and therapeutic development.

Neuroscientist and co-founder of Mindtrix. Studied primate visual-system structure and function and neural encoding and decoding at the Salk Institute before founding the company with Liu Bing in 2024.

Neuroscientist and co-founder of Mindtrix. Conducted implantable brain-computer interface research at the University of California, Berkeley and Duke University before returning to the Chinese Academy of Sciences Institute of Automation in 2023.

Marine Larnaudie is published by Sofilaro Calen as Apprentice Analyst / Middle Office. The current public directory identifies this role but does not supply a longer career biography.

Cédric Mirri is published by Sofilaro Calen as Analyst / Middle Office. The current public directory identifies this role but does not supply a longer career biography.

Solenn Marcel is published by Sofilaro Calen as Analyst / Middle Office. The current public directory identifies this role but does not supply a longer career biography.

Julie Streiff is published by Sofilaro Calen as Analyst / Middle Office. The current public directory identifies this role but does not supply a longer career biography.

Published as Lt. Gen. AK Bhalla, former Director General of the Defence Intelligence Agency. The manager publishes initials rather than an expanded given name.

Published Industrial47 advisor whose current external role is product at Nvidia.

Solo general partner investing in Indian frontier technology. Former scouting director at Antler India, entrepreneur and Indian Army Reserves major; alumnus of BITS Pilani and the Indian Military Academy.

Matthieu Rudi is published by Sofilaro Calen as Administrative and Finance Director. The current public directory identifies this role but does not supply a longer career biography.

Lucie Ayala is published by Sofilaro Calen as Investment Director, Innovation. The current public directory identifies this role but does not supply a longer career biography.

Lucas Grillard is published by Sofilaro Calen as Investment Director, Innovation. The current public directory identifies this role but does not supply a longer career biography.

Constance Arnal is published by Sofilaro Calen as Fund Director, Renewable Energy. The current public directory identifies this role but does not supply a longer career biography.

Betty Bonnardel is published as UKI2S Space Advisor and Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. She founded AB5Consulting and FarmerCharlie, combining space and satellite expertise with engineering, energy and agricultural technology. Her training includes aeronautical/space engineering and an MBA. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Nicholas Barsby is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His published background includes Army logistics, defence-science advisory work and programme management. His DASA chief-of-staff responsibilities span budgeting, performance and communications. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Marcel Gehrung is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His background combines a Cambridge doctorate in healthcare machine learning with co-founding and leading Cyted, developing diagnostic technology for digestive disease. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Ruth Elliot is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. She trained in accountancy at Deloitte and subsequently held senior public-sector finance roles, including deputy CFO at UKRI and finance/corporate-services leadership at UKAEA. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Peter Hamley is the founder and CEO of Scripta Therapeutics, an Oxford techbio company developing transcription-factor-directed therapeutics for neurodegenerative diseases.

Joyeeta Das is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. Her technology and entrepreneurship career includes Cisco, founding SuperPitch and leading SamundraOceans, alongside data and AI advisory work and support for women innovators. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Colin Story is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His career includes GEHealthcare, Oxford technology transfer, OrganOx and co-founding OxSonics, followed by therapeutic-company board and executive work. The fund records his advisory appointment inNovember2023. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Alison Campbell is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. Her technology-transfer career includes KnowledgeTransferIreland, the MedicalResearchCouncil and King’sCollegeLondon. She became the GovernmentOfficeforTechnologyTransfer chief executive in2022. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Massimo Noro is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. He represents STFC in UKI2S and leads business development at Daresbury, following global industrial research at Unilever. His scientific training includes a UCLA physical-chemistry doctorate. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Eddie Alleyn is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. He previously led HMGCC during2011–2016 following government work in defence, security and foreign affairs, and now advises technology ventures; he is an IET Fellow. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

John Tingay is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His engineering experience spans semiconductor and electronics equipment, wafer-level packaging, imaging and particle-accelerator systems, including bringing new technologies into commercial production. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Nick Bassett is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His published career includes BBSRC innovation leadership, InnovateUK investor-partnership development, diagnostic-device work and co-founding an immunohistochemistry business. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Tony Raven is published as UKI2S Chair of Board and Consultation Committee within the UK Innovation & Science Seed Fund ecosystem. His career combines research, entrepreneurship and university technology transfer. He led Cambridge Enterprise for tenyears until2021 and helped establish Cambridge Innovation Capital and the TenU university-commercialisation network. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Malika Arshad supports Future Planet Capital’s fundraising, investor engagement and investment work. She previously worked in investment banking at Credit Suisse.

Priya Guha is published as Investment Governance Board Member with Future Planet Capital. Her experience spans technology leadership and public oversight, including UKRI, Reach and TechSheCan; she received an MBE in2021. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Jerome S. Engel is published as Investment Governance Board Member with Future Planet Capital. His work centres on innovation, entrepreneurship and venture capital through teaching and advisory work for business and government. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Paul Abberley is published as Chair of Investment Governance Board with Future Planet Capital. His professional experience includes senior institutional asset-management and investment leadership at ABNAmro, Aviva and CharlesStanley. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Nat Wei is published as Advisory Board Member with Future Planet Capital. He is a member of the House of Lords with experience in government advisory work and parliamentary business groups. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Sugata Mitra is published as Advisory Board Member with Future Planet Capital. He is known for educational-technology research and the Hole in the Wall project and received the TED Prize in2013. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Robin Chase is published as Advisory Board Member with Future Planet Capital. She co-founded and previously led Zipcar, bringing operating experience in shared transport. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Fabien Mansalier is published by Sofilaro Calen as Fund Director, Renewable Energy. The current public directory identifies this role but does not supply a longer career biography.

Christophe Romeyer is published by Sofilaro Calen as Fund Director, Development and Succession. The current public directory identifies this role but does not supply a longer career biography.

Manuel Potier is published by Sofilaro Calen as Fund Director, Development and Succession. The current public directory identifies this role but does not supply a longer career biography.

Patrice Roch is published by Sofilaro Calen as Managing Director. The current public directory identifies this role but does not supply a longer career biography.

Denis Martins is published by Sofilaro Calen as President of platform (public title; statutory SAS president is Sofilaro Gestion). The current public directory identifies this role but does not supply a longer career biography.

Norman Foster is published as Chair of Advisory Board with Future Planet Capital. He is an architect and design-practice leader and established the Norman Foster Foundation. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Abi Wye is published as Network Director with Future Planet Capital. Her experience spans government, NGOs and private-client networks; she previously served as political private secretary to DavidCameron. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Mark White is an investment director at Future Planet Capital and leads UKI2S fusion investing. His background includes UK investment banking and NESTA investment operations.

Thomas Storey is published as Senior Associate with Future Planet Capital. His earlier work as a principal consultant at London Economics involved strategic analysis of the space sector. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Tony Stott is published as Investment Director with Future Planet Capital. He has extensive company-board experience and led a Midlands venture group from1998. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Rebecca Starkings is published as Compliance Officer, MLRO with Future Planet Capital. Her compliance career includes more than15years in financial-crime controls, integrity, due diligence and investment monitoring. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Huw Sparks is published as Investment Manager with Future Planet Capital. His work centres on the Midlands Engine Investment Fund; earlier experience includes boutique venture consulting and economics/politics studies at Birmingham. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Luize Silina is published as Investment Analyst with Future Planet Capital. She works in the regional investment team based in Birmingham. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Alex Shadbolt is published as Investment Manager & Impact Lead with Future Planet Capital. He works on investment management and the firm’s impact framework, including investment decisions, internal processes and portfolio monitoring. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Oliver Sexton is published as Investment Director with Future Planet Capital. He is an experienced life-sciences and deep-technology investor with UKI2S investment-committee responsibilities, earlier buy-side analysis and strategy experience. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Ed Phillips is Future Planet Capital’s global managing director and a founding team member. He invests through its global, Blue Ocean and Challenge Response strategies and has a molecular genetics research background.

Jordan Ong is published as Investment Associate with Future Planet Capital. He invests in the West Midlands through MEIF and co-investment programmes, following work at the Development Bank of Wales. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Andrew Muir is published as Investment Director with Future Planet Capital. His career combines chemistry research at Oxford, industry work at Zeneca and a US startup, and venture investment at NESTA. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Peter Mitchell is published as Director, Data Science & Technology with Future Planet Capital. His research background includes statistical projects for the UK Cabinet Office and OECD, postgraduate study at Harvard and doctoral work at Oxford. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Samantha Mills is published as Finance Associate with Future Planet Capital. Her finance work is supported by an AAT Level4 professional-accounting qualification. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Sam Martin is published as Portfolio Director with Future Planet Capital. He works with UKI2S portfolio companies on development and investment readiness. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Hassan Mahmudul is published as Investment Manager with Future Planet Capital. His work supports UKI2S; earlier experience includes founding two startups and venture scouting for Ada Ventures. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Rupert Lyle is published as Investment Director with Future Planet Capital. His investment and portfolio-management career spans more than30years, and he leads the West Midlands Co-Investment Fund. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Alex Leigh is published as Managing Director, National with Future Planet Capital. His background combines mechatronics engineering, an MBA and venture/private-equity investment in deep technology. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Surjit Kooner is published as Managing Director, Regional with Future Planet Capital. He is a chartered accountant with fundraising-advisory experience, MEIF fund-principal responsibilities and investment-committee membership. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

David Knox is published as Director with Future Planet Capital. He founded and leads Lazarus after more than20years in financial-market advisory, including research leadership and executive-committee membership at J.P.Morgan Cazenove. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Emma Jacobs is published as Executive Assistant with Future Planet Capital. She assists the executive chairman and brings more than30years of assistant experience, principally in finance. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Shruti Iyengar is published as Investment Director with Future Planet Capital. She supports UKI2S following venture investing at Sustainable Ventures, including responsibility for a36-company portfolio and development of impact measurement. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Sakura Holloway was Start Codon partner and head of diligence in its2019–2020 period. Her current UKI2S biography describes former Start Codon healthcare deal sourcing, prior Manchester Innovation Factory and OneVentures roles, Benitec IP work, molecular-biology background and IP-law masters training. Current UKI2S/Future Planet roles are preserved separately; no exact historical departure date inferred.

Jessica Hill is published as Director of IR & Strategic Partnerships with Future Planet Capital. Her earlier work was in Gresham House’s housing business; she studied politics and leadership at Exeter. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Darren Heffernan is published as Director of Finance & Operations with Future Planet Capital. His accounting and finance career includes Asian financial reporting at an international bank and large transformation programmes. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Daniel Gaize is published as Investment Associate with Future Planet Capital. He works on the Midlands Engine Investment Fund and brings experience from LGPS Central, family offices and Standard Life Investments; he holds the CAIA designation. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Julie Davies is published as Fund Accountant with Future Planet Capital. She is a chartered accountant and tax adviser whose Deloitte and EY experience focused on entrepreneurial companies. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Andrew Carpenter is published as General Counsel with Future Planet Capital. His professional background is corporate law, including partner positions at international law firms and transactions in Britain and abroad. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Andy Bard is published as Portfolio Manager with Future Planet Capital. His accounting training was at KPMG, followed by work managing and realising RBS equity investments; he studied accounting and finance at Leeds. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Douglas Hansen-Luke founded Future Planet Capital in 2015 and is its executive chairman. His background combines international finance, entrepreneurship and research into institutional investment.

Emily Thompson is a Northern Gritstone investment manager focused on commercialising life sciences and deep technology. She previously invested through Edinburgh’s Old College Capital and worked in university technology transfer.

Jim O’Neill chairs Northern Gritstone. His career includes leadership in Goldman Sachs research and asset management and public work on regional development and antimicrobial resistance.

Duncan Johnson is Northern Gritstone’s founding chief executive and previously led Caledonia Private Capital.

Khadija Ashfaq invests in science and technology businesses at Northern Gritstone, having previously backed North-East England companies at Northstar Ventures.

Timothy M. Wright, M.D. Timothy M. Wright, MD, has been chief R&D officer at Regulus Therapeutics, a clinical stage biotech in San Diego, CA, since 2016. Over the past two decades, he has served in leadership positions from discovery research to late stage pharmaceutical development at Pfizer (2001-2004), Novartis (2004-2015), and the California Institutes for Biomedical Research (Calibr, 2015-2016). In these roles he has contributed to the development of numerous innovative medicines from concept to market. A native of Wilmington, Delaware, Wright attended the University of Delaware (BA, Biology) and received his medical and research training at the Johns Hopkins University School of Medicine (MD, Rheumatology, Immunology, Molecular Biology) and the Medical College of Virginia (Internal Medicine). In his early research career, he made advances in the understanding of the biochemistry and molecular biology of signal transduction. Wright held academic positions as a physician-scientist at Johns Hopkins and the University of Pittsburgh where his research was focused on the humoral, cellular, and molecular aspects of immune responses in autoimmune diseases. While at the University of Pittsburgh, he led the formation of the Pittsburgh Arthritis Institute, was chief of Rheumatology and Clinical Immunology and was the recipient of the Margaret J. Miller endowed Professorship for Arthritis Research, before moving to the pharmaceutical industry in 2001. Wright serves on the Board of Directors for Schrödinger, Inc. and ENYO Pharma, and as a scientific advisor to several academic and industry organizations.

Harold Varmus, M.D. Harold Varmus was co-recipient of the 1989 Nobel Prize in Physiology or Medicine for studies of the genetic basis of cancer. In April 2015, he joined the Meyer Cancer Center of Weill Cornell Medicine as the Lewis Thomas University Professor of Medicine. He is also a senior associate member of the New York Genome Center, where he helps develop programs in cancer genomics. Previously, Varmus was the director of the National Cancer Institute for five years, the president of Memorial Sloan-Kettering Cancer Center for 10 years, and director of the National Institutes of Health for six years. A graduate of Amherst College and Harvard University in English literature and of Columbia University in medicine, he trained further at Columbia University Medical Center, the National Institutes of Health, and the University of California San Francisco (UCSF), before becoming a member of the UCSF basic science faculty for more than two decades. He is a member of the U.S. National Academies of Sciences and Medicine, and he is involved in several initiatives to promote science and health in developing countries. He also serves on advisory groups for several academic, governmental, philanthropic, and commercial institutions, including as co-chair of the Mayor’s LifeSci NYC and member of advisory boards for Chan-Zuckerberg Science and three biotechnology companies (Surrozen, Dragonfly, and PetraPharma). The author of about 400 scientific papers and five books, including a recent memoir, The Art and Politics of Science, Varmus was a co-chair of U.S. President Obama’s Council of Advisors on Science and Technology, a co-founder and chairman of the board of the Public Library of Science, and chair of the Scientific Board of the Gates Foundation Grand Challenges in Global Health.

Eric G. Pamer, M.D. Eric G. Pamer received his M.D. from Case Western Reserve University Medical School and completed clinical training in internal medicine and infectious diseases at University of California San Diego (UCSD) Medical Center. He was a postdoctoral fellow with Charles E. Davis at UCSD, with Maggie So at Scripps Research Institute, and with Michael Bevan at the University of Washington before he moved to Yale University. In 2000, he moved his laboratory to Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, where he has been chief of infectious diseases and, more recently, head of the Division of Subspecialty Medicine. Pamer initially studied T cell responses to Listeria monocytogenes infection, demonstrating the efficiency of antigen presentation and the impact of antigen presentation and inflammation on T cell response magnitudes. Upon moving to MSKCC, he extended his research to inflammatory monocytes. In a series of studies, Pamer demonstrated that inflammatory monocytes differentiate into TNF and iNOS producing dendritic cells in response to L. monocytogenes. He demonstrated that CCR2 chemokine receptors drive monocyte emigration from bone marrow but not, as previously assumed, immigration into infected tissues. Pamer showed that bone marrow mesenchymal cells have hair-trigger responses to TLR-ligands and produce CCL2, driving monocytes into the bloodstream. He demonstrated that monocytes transport fungal spores and Mycobacterium tuberculosis from the lung to mediastinal lymph nodes and, during Mtb infection, transfer antigen to dendritic cells to prime CD4 T cells in lymph nodes. Because infections caused by highly antibiotic-resistant pathogens are a growing problem, Pamer has focused on Vancomycin-resistant Enterococcus (VRE) and Clostridium difficile infections and the defensive roles of mucosal immunity and the microbiota. A seminal study demonstrating that antibiotics reduce intestinal immune defenses and facilitate VRE infection was followed by discovery of commensal bacterial species that enhance antimicrobial defenses. Pamer focused on patients undergoing bone marrow transplantation and discovered dramatic microbiota diversity losses following transplantation. He also demonstrated that diversity loss is associated with increased mortality. Pamer’s work has led to the first randomized clinical trial to determine the feasibility and benefit of reintroducing a patient’s own intestinal microbiota following bone marrow transplantation.

Francine Ntoumi, Ph.D., HDR, PvDz, FRCPedin Francine Ntoumi serves as the chair and head of research of the Congolese Foundation for Medical Research. Born in Brazzaville in the Republic of the Congo, Ntoumi studied in France and got habilitation at University ParisVI (2002) and at University of Tübingen in Germany (2014). In Congo, Gabon, and Germany, she worked as a researcher, and she held positions in international organizations in the Netherlands and Tanzania from 2005 to 2010. Also during this time, she was the first African leader of the Multilateral Initiative on Malaria (MIM). During her career in malaria research, she trained many African scientists in various disciplines such as immunology and molecular epidemiology. Since 2009, Ntoumi has been highly involved in developing health research capacities in Central Africa through the regional network of excellence, the Central Africa Network on Tuberculosis, HIV/AIDS, Malaria (CANTAM). In the Republic of Congo in 2008, she created the Congolese Foundation for Medical Research (FCRM), which supports health research activities in the country. Her institution has established the first molecular biology lab at the University Marien Ngouabi, where she is senior lecturer. She is also highly engaged in promoting gender balance in science in the African region through an important program, “To make Science, a female ambition.” Ntoumi is member of several scientific and advisory committees and is involved in many international scientific networks in Africa, Europe, and the United States. She is a fellow of the African Academy of Science. In recognition of her efforts in developing research capacities in Africa, Ntoumi received the prestigious African Union Kwame Nkrumah Regional Scientific Award for women (2012), Germany’s Georg Forster Prize (2015), France’s Christophe Merieux Prize, and the Gold Medal for her contribution in science (research, training, advocacy, and transforming the environment) by the president of the Republic of Congo (2016).

Shabir A. Madhi, M.B.B.C.H., FCPaeds, Ph.D. Shabir Madhi is professor of vaccinology at the University of the Witwatersrand in Johannesburg. He also holds the positions of director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit and he is research chair in vaccine preventable diseases at the Department of Science and Technology at the National Research Foundation. He is the immediate past director of the National Institute for Communicable Diseases (2011 to 2017), and he currently serves as the chair of the National Advisory Group on Immunization in South Africa. Author of more than 350 scientific publications, his research focus has been on epidemiology and clinical development of vaccines against pneumonia, diarrheal disease, and for maternal immunization. These studies have been pivotal to informing WHO and SAGE policy on the use of such vaccines in low-middle income countries. He has served as a temporary consultant/technical adviser to WHO in the field of pneumonia and vaccines. His scientific awards include European Society for Infectious Diseases Young Investigators Award (2006), as well as a number of national awards, including the 2009 National Science and Technology Forum: TW Kambule Award (2009), National Research Foundations President’s Award: Transformation of the Science Cohort (2010), Medical Research Council Lifetime Award platinum medal (2013), and the European and Developing Countries Clinical Trial Partnership Award for Scientific Leadership (2016). He is an elected member of the Academy of Science of South Africa (2012) and the Royal Society of South Africa (2016), and in 2017 he was elected as a fellow of the World Academy of Sciences.

Salim S. Abdool Karim, M.B.Ch.B, Dip.Data (computer science), M.S., M.Med, F.F.P.H.M., Ph.D., D.Sc.(hc) Salim S. Abdool Karim is a South African clinical infectious diseases epidemiologist who is widely recognized for his research contributions in HIV prevention and treatment. He is director of the Centre for the AIDS Program of Research in South Africa (CAPRISA) and CAPRISA professor of global health at Columbia University. He is also pro vice-chancellor (research) at the University of KwaZulu-Natal, South Africa, and adjunct professor of medicine at Cornell University in New York. He has served as the president of the South African Medical Research Council and is an associate member of the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard University. His clinical research on tuberculosis-HIV treatment has shaped international guidelines on the clinical management of co-infected patients. He was co-leader of the CAPRISA 004 tenofovir gel trial that provided proof-of-concept that antiretrovirals can prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. He is co-inventor on patents that have been used in several HIV vaccine candidates and in passive immunization strategies with broadly neutralizing antibodies. Abdool Karim is chair of the UNAIDS Scientific Expert Panel, WHO’s HIV Strategic and Technical Advisory Committee, and the WHO Tuberculosis-HIV Task Force. He serves on the boards of several journals, including the New England Journal of Medicine, Lancet Global Health, Lancet HIV, and mBio. He is a member of the Royal Society of South Africa, Academy of Science of South Africa, African Academy of Sciences, and the World Academy of Sciences (TWAS). He is a member of the U.S. National Academy of Medicine, the American Academy of Microbiology, and the Association of American Physicians. His awards include the TWAS Prize in Medical Sciences, the African Academy of Science’s Olusegun Obasanjo Prize for Scientific Discovery and Technological Innovation, the Science for Society Gold Medal Award from the Academy of Science in South Africa, the Platinum Medal Lifetime Achievement Award from the South African Medical Research Council, and Columbia University’s Allan Rosenfield Alumni Award for Excellence. The African Union awarded him the Kwame Nkrumah Continental Scientific Award, the most prestigious scientific award in Africa.

Margaret A. Hamburg, M.D. Margaret A. Hamburg, an internationally recognized leader in public health and medicine, is the foreign secretary for the U.S. National Academy of Medicine and the president of the American Association for the Advancement of Science (AAAS). She is the former commissioner of the U.S. Food and Drug Administration (FDA), having stepped down from that role in April 2015 after almost six years of service. As FDA commissioner, she was known for advancing regulatory science, streamlining and modernizing the FDA’s regulatory pathways, and globalization of the agency. Before joining the FDA, Hamburg was founding vice president and senior scientist at the Nuclear Threat Initiative, a foundation dedicated to reducing nuclear, chemical, and biological threats. Previous government positions include assistant secretary for planning and evaluation at the U.S. Department of Health and Human Services, health commissioner for New York City, and assistant director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Hamburg earned her B.A. from Harvard College and her M.D. from Harvard Medical School, and she completed her medical residency at Weill Cornell Medical Center. She is a fellow of the American Association for the Advancement of Science and the American College of Physicians, and is an elected member of the Council on Foreign Relations and the National Academy of Medicine. Hamburg sits on the boards of the Commonwealth Fund, the Simons Foundation, the Urban Institute, and the American Museum of Natural History. She is also a member of the Harvard University Global Advisory Council, the Global Health Scientific Advisory Committee for the Gates Foundation, the Harvard Medical School Board of Fellows, and the World Dementia Council. She is the recipient of multiple honorary degrees and numerous awards.

Yvonne Greenstreet, M.B.Ch.B, M.B.A. Yvonne Greenstreet has over 25 years of global experience in the healthcare and pharmaceutical industries, spanning drug development, general management, and corporate strategy. She has led product development and commercialization teams in a wide range of therapy areas of both small molecules and biologics and over the course of her career has brought numerous new medicines to market. Greenstreet is chief operating officer at Alnylam Pharmaceuticals. She was the founder and managing director of Highgate LLC, working with life sciences companies to help develop strategies that transform businesses, bring medicines to market, and maximize shareholder value. Previously, Greenstreet was senior vice president and head of Medicines Development at Pfizer from 2011-2013 and a member of the executive team with accountability for the $16bn Specialty Business. Greenstreet was at GlaxoSmithKline (GSK) from 1992- 2010, most recently as senior vice president and chief of strategy for Research and Development, and as a member of the product management board. She previously served in various positions of increasing responsibility at GSK, including senior vice president for Medicines Development, where she led the creation of a global unit with the responsibility for the development and commercialization of new products across a wide range of therapeutic areas. Greenstreet holds a bachelor of Medicine, bachelor of Surgery from the University of Leeds, United Kingdom and MBA from INSEAD, France.

Tumani Corrah, M.D., Ph.D., F.R.C.P., P.P.W.A.C.P. Tumani Corrah is the unit director of the Medical Research Council Unit in the Republic of the Gambia. He joined the unit in 1982 as a junior clinician and progressed through the ranks as a research clinician and senior clinician, director of clinical services, and acting unit director. In 2004, he became the first African director of the U.K. Medical Research Council Unit in the Gambia. For more than two decades, Corrah has retained active research interests in tropical and infectious diseases, including tuberculosis, HIV, and malaria. His Ph.D. was groundbreaking, as he undertook one of the first trials of immunotherapy as an adjunct to the treatment of tuberculosis in Africa. He is a joint gold medal winner from the International Medical Informatics Association. He has served on the committees of many international organizations, including the African Aids Research Network (vice president), WHO Tuberculosis Task Force in Africa (member), Royal College of Physicians of London (international adviser), Royal Society of Tropical Medicine and Hygiene (international adviser), Visiting Committee of the London School of Hygiene and Tropical Medicine (member), and Partnership Board of the EDCTP (member). Corrah served as president of the West African College of Physicians and is currently the director of the college’s international office. An expert on research governance, he is a long-standing member of the Gambia government/MRC Ethics Committee, for which he served four years as chairman. He has strong links with governmental and nongovernmental organizations in Africa and throughout the world. An expert in capacity building, Corrah has been successful in establishing a number of productive, mutually beneficial North-South collaborations.

Zulfiqar A. Bhutta, M.B.B.S., D.C.H., F.R.C.P., F.R.C.P.C.H., F.C.P.S., F.A.A.P., Ph.D. Zulfiqar A. Bhutta is the Robert Harding Inaugural Chair in Global Child Health at Toronto’s Hospital for Sick Children, co-director of the SickKids Centre for Global Child Health, and the founding director of the Centre of Excellence in Women and Child Health at the Aga Khan University. He also holds adjunct professorships at several leading universities, including the School of Public Health at Johns Hopkins University, Tufts University, Boston University School of Public Health, University of Alberta, and the London School of Hygiene and Tropical Medicine. He is Distinguished National Professor of the Government of Pakistan and was the founding chair of Pakistan’s National Research Ethics Committee from 2003 to 2014. Bhutta was a member of the Independent Expert Review Group (iERG) appointed by the UN Secretary General for monitoring global progress in maternal and child health MDGs (2011 to 2015). He represented the global academic and research organizations on the Global Alliance for Vaccines and Immunizations (Gavi) board, and he also serves on Gavi’s Evaluation Advisory Committee. Bhutta was the co-chair of the Global Countdown for 2015 and 2030 Initiatives (2006 to 2017). He is the co-chair of the Maternal and Child Health oversight committee of WHO’s Eastern Mediterranean Region and the chairman of the Coalition of Centres in Global Child Health, whose secretariat is based at Toronto’s Hospital for Sick Children. He is a technical member of the high-level UN Health and Human Rights committee and an executive committee member of Partnership for Maternal, Newborn, and Child Health (PMNCH). Bhutta was educated at the University of Peshawar and obtained his Ph.D. from the Karolinska Institute, Sweden. He is a fellow of the Royal College of Physicians (Edinburgh and London), the Royal College of Paediatrics and Child Health (London), American Academy of Pediatrics, and the Pakistan Academy of Sciences. He heads a large research team in Pakistan working on issues of maternal, newborn, and child survival and nutrition globally and regionally. Bhutta has served as a member of WHO’s Global Advisory Committee for Health Research, the board of the Child and Health and Nutrition Initiative of the Global Forum for Health Research, and the steering committees of the International Zinc and Vitamin A Nutrition Consultative Groups. He was a founding board member of the PMNCH and a board member of the International Center for Diarrheal Diseases Research (2011 to 2017). Bhutta was a member of the WHO Strategic Advisory Committee for Vaccines (SAGE) from 2010 to 2015 and the Advisory Committee for Health Research of the WHO EMRO. He is the former president of the Commonwealth Association of Paediatric Gastroenterology and Nutrition (CAPGAN) and the Federation of Asia-Oceania Perinatal Societies (FAOPS). He is the current president of the International Pediatric Association (2016 to 2019), and he serves as a leading voice for health professionals supporting integrated maternal, newborn, and child health globally. Bhutta is on several international editorial advisory boards, including the Lancet, BMJ, PLoS Medicine, PLoS ONE, BMC Public Health, and the Cochrane CDPLG and ARI groups. He has published eight books, 88 book chapters, and more than 800 indexed publications to date, including more than 150 in the world’s leading journal, Lancet. He is one of the most highly cited academics in global health (H index 117, i10 index 537, with more than 72,000 citations) and was ranked among the top 1 percent of highly cited researchers globally by the Web of Science in 2017. He has been a leading member of major Lancet series on child survival (2003), newborn survival (2005 and 2014), undernutrition (2008 and 2013), primary care (2008), stillbirths (2011 and 2016), and Pakistan (2013). He has also been a leading member of the recent series on childhood diarrhea and pneumonia (2013) and early child development (2016), and Lancet commissions on education for health professionals for the 21st century (2010), women and health (2015), indigenous health (2016), and adolescent health (2016). He has won several awards, including the Tamgha-i-Imtiaz (Medal of Excellence) by the president of Pakistan for contributions to education and research (2000), the president of Pakistan’s gold medal for contributions to child health in Pakistan (2004), and the Outstanding Pediatrician of Asia award by the Asia Pacific Pediatric Association (2006). He is the first dual recipient of the Aga Khan University Distinguished Faculty Award for Research (2005) and Award of Distinction (2012). Bhutta was awarded the inaugural Programme for Global Pediatric Research Award for Outstanding Contributions to Global Child Health (2009) and the Kenneth Warren Prize for the best systematic review of community-based interventions by the Cochrane collaboration (2011). Bhutta was awarded the Global Advocacy Prize by the Royal College of Paediatrics and Child Health (2012), the American Academy of Pediatrics’ Sam Fomon Award for lifetime contributions to nutrition research (2014), the WHO Ihsan Dogramaci Family Health Award (2014), the inaugural TUBA Academy of Sciences Award for global contributions to health and life sciences (2015), University of Toledo Medical Missions Hall of Fame Award (2016), and the Geneva Forum for Health Award for contributions to maternal and child health globally (2016). In August 2016, Bhutta was recognized with the president of Pakistan Pride of Performance Award for contributions to education and health. In November 2016, the World Academy of Sciences (Trieste) awarded him the TWAS Prize in Medical Sciences, and in 2017 the Pakistan Council for Science and Technology rated Bhutta as the highest ranking scientist from Pakistan across all disciplines. In November 2017, he was recognized by the Senate of Canada with its Canada 150 Medal for contributions to global child health. Bhutta’s research interests include newborn and child survival, maternal and child undernutrition, and micronutrient deficiencies. He leads large research groups based in Karachi, Nairobi, and Toronto, with a special interest in research synthesis, expanding evidence-based interventions in community settings, and implementation research in health systems research. His work on community health staff and outreach services has influenced integrated maternal and newborn outreach programs for marginalized populations globally. His group’s work with WHO and PMNCH in developing consensus-based essential interventions for women, children, and adolescents is the dominant set of agreed interventions guiding global policy.

Alan Bernstein, O.C., O.Ont., Ph.D,. FRSC Alan Bernstein is president of the Canadian Institute for Advanced Research (CIFAR), one of Canada’s major global research assets. From 2008 to 2011, Bernstein was the executive director of the Global HIV Vaccine Enterprise, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine. Previously, he served as the founding president of the Canadian Institutes of Health Research (2000 to 2007), Canada’s federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada. After receiving his Ph.D. from the University of Toronto, and following postdoctoral work in London, Bernstein joined the Ontario Cancer Institute (1974 to 1985). In 1985, he joined the new Samuel Lunenfeld Research Institute in Toronto. He was named associate director in 1988, and he served as director of research from 1994 to 2000. Bernstein has written more than 225 scientific publications and has made extensive contributions to the study of stem cells, hematopoiesis, and cancer. He chairs or is a member of advisory and review boards in Canada, as well as in Italy, the U.K., and the United States. Bernstein has received numerous awards and honorary degrees for his contributions to science, including the 2008 Gairdner Wightman Award, induction into the Canadian Medical Hall of Fame, and the Henry G. Friesen International Prize in Health Research. He is a senior research fellow of Massey College and in 2002, he was appointed an officer of the Order of Canada.

John Bell, G.B.E., F.R.S., FMedSci (Chair of Committee) John Bell is the Regius Professor of Medicine at Oxford University. Bell went to Oxford as a Rhodes Scholar to train in medicine and undertook postgraduate training in London and at Stanford University. At Stanford, he developed research interests in the area of immunology and genetics, with a particular focus on characterizing the molecular events associated with susceptibility to autoimmune diseases. He returned to Oxford as a Wellcome Trust senior clinical fellow in 1987 and was elected to the Nuffield Professorship of Clinical Medicine in Oxford in 1992. In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centers for complex trait common disease genetics. In 2002, he became the Regius Professor of Medicine. Bell served as president of the Academy of Medical Sciences from 2006 to 2011. He was responsible for the working party that produced the academy’s highly influential “Strengthening Clinical Research” report that highlighted the need for the U.K. to focus some of its attention on developing expertise in translational research. In 2006, he was appointed by the chancellor of the exchequer to chair the Office for the Strategic Coordination of Health Research (OSCHR), and in December 2011, he was appointed one of two U.K. Life Sciences Champions by the prime minister. In collaboration with industry, academia, charity, and research organizations, Bell drafted the U.K. Life Sciences Industrial Strategy, which provides recommendations to the government on the long-term success of the life sciences sector. The report was published on August 30, 2017. In 2008, he was made a fellow of the Royal Society and a Knight Bachelor for his services to medical science. He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research, and the life science industry. Bell has been involved extensively in the development of research programs in genetics and genomics and in the development of a clinical research program across the U.K. He sits on a range of advisory panels for public and private sector bodies responsible for biomedical research in Canada, Denmark, France, Singapore, Sweden, and the U.K, and he is a founding director of three biotechnology start-up companies.

Dr Ann Taylor is an experienced clinical investigator and pharmaceutical executive with 20 years experience in the pharmaceutical industry, serving in multiple leadership roles at multiple companies. She was Chief Medical Officer at AstraZeneca from 2019-2021 where she was responsible for employee and patient safety during the COVID epidemic, AstraZeneca’s Patient Safety, Quality Assurance, and Regulatory Policy organizations, and the overall Benefit Risk assessment of our medicines. Prior to joining AstraZeneca in 2018, Ann was Vice President and Global Head of the Program Office for the Novartis Institutes for BioMedical Research (NIBR), responsible for portfolio management, strategy, and project management. She also previously served as Global Head, Translational Medicine at NIBR, after having positions of increasing responsibility in early clinical development at Pfizer Global Research and Development. Ann received her M.D. from Harvard Medical School, after receiving her B.A. in Biology magna cum laude from the University of California, San Diego. She completed her internship and residency in Internal Medicine, and her fellowship in Endocrinology and Metabolism at Massachusetts General Hospital, where she served on the faculty as a clinician, investigator, teacher, and administrator for 11 years. She is passionate about bringing the patient voice to clinical trials and has a particular interest in health equity and women’s health. Ann currently serves on the Boards of Comanche Biopharma and UnLearn AI, as well as two non-profits, the TBAlliance and the New England Advisory Board of the Trust for Public. She also serves as Co-Chair of the National Academies of Science, Engineering and Medicine Forum on Drug Discovery, Development, and Translation and is a member of the Alumni Council at Harvard Medical School.

Mumbai, India Sandeep is a Senior Advisor and Investment Committee Member at Avaana Capital, India’s leading early-stage climate action and sustainability fund. He is a Board Member of Titan Company Limited, chairs the Risk Management Committee and is a member of the Audit and Nomination & Remuneration Committees. He is on the board of HT Media, India’s largest listed media company. Sandeep is also an independent investment committee member of the Mars Equity Dragon Fund and a Governing Council Member of Marico Innovation Foundation. He is a Board Member and leads healthcare philanthropy at ACT Grants, a platform to accelerate the deployment of innovative digital solutions in the public domain in India. The focus in public health is in the areas of Tuberculosis, Oncology, Mental Health and Rural Access. Sandeep has 35 years of experience across venture capital, entrepreneurship, and management consulting. He co-founded Nexus Venture Partners in 2006 and grew it to $1.5B of AUM, was a General Partner till 2021, and is now a Senior Advisor. Prior to Nexus, he co-founded eVentures India in 1999. eVentures was one of the earliest Indian VCs and backed market leaders like MakeMyTrip, NTT NetMagic Solutions and Firstsource/CustomerAsset. Sandeep received an MBA (with Distinction) from The Wharton School of the University of Pennsylvania with a dual Major in Finance and Marketing, and a BS in Electrical Engineering from Stanford University, where he was elected to Phi Beta Kappa and Tau Beta Pi. He is the past President of the Stanford Alumni Association of India and a Stanford Associate.

London Nimit Shah joined Vivo Energy as CFO in May 2024. Before joining Vivo Energy he was a partner in the investment team and Head of Debt Capital Markets at Africa-focused private equity firm, Helios Investment Partners. At Helios, he has led deals in more than 30 African markets, worth around $2bn of value. These include GBFoods Africa, Interswitch, Continental Outdoor, and OVH Energy. He was also involved in the original deal when Vitol and Helios acquired Shell’s downstream Africa business to create Vivo Energy in 2011. Nimit holds an MBA from Wharton School of Business, and an MA in Economics and Management from Oxford University.

Keith Matthews manages the foundation’s legal team and oversees a broad range of legal, transactional, policy, operational, and programmatic matters that affect the foundation and its subsidiaries and their ability to achieve their respective missions. Keith serves on the board of Bill & Melinda Gates Agricultural Innovations, a foundation subsidiary that focuses on developing agricultural technologies and innovations. He also serves on the investment committees of the foundation’s Strategic Investment Fund and the Innovative Financial Instruments team. Before Keith joined the foundation, his legal work focused on corporate transactions and governance matters. He counseled private equity investors on a wide range of transactions, including growth equity and venture capital investments and mergers and acquisitions. Over the course of his career, he was seconded to the African Development Bank in Tunisia, where he represented the bank in public and private financings in sub-Saharan Africa, and he worked in Singapore as a lawyer focused on project financings. Keith has also worked as a management consultant and a commercial banker based in New York. Keith has a B.S. in finance from the Wharton School at the University of Pennsylvania and a J.D. from the University of Michigan.

Tracia Luh leads a team that provides financial and strategic planning and analytical support across the foundation’s work in global health. She also leads the foundation’s Business Development & Licensing team, which structures investments with private-sector business partners to advance the foundation’s mission and charitable purpose. Tracia joined the foundation in 2016 as chief financial officer of the U.S. Program, which largely focuses on education. Earlier, she served as CFO of Andela, a talent accelerator funded by the Chan Zuckerberg Initiative and other investors that trains software developers in Africa and places them with leading global companies. She also served as CFO and senior vice president of corporate development at Newsweek, a division of Graham Holdings / Washington Post, where she was hired to lead a financial review of strategic alternatives that culminated in the sale of the division. From 2000 to 2009, Tracia held senior financial positions at ESPN/Disney, assessing operating performance and evaluating strategic transactions and investments. She began her career in the Global Fixed Income departments at Merrill Lynch and Chase / J.P. Morgan, analyzing companies and publishing investment recommendations. Tracia has a bachelor's degree from the Wharton School at the University of Pennsylvania and an MBA from the Kellogg School of Management at Northwestern University. She serves on the boards of the YMCA of Greater Seattle, which manages 13 Seattle-area branches, and Lincoln Center Education, which provides arts education programs to underserved schools and communities.

Sundar Kodiyalam is a seasoned investor and biotechnology executive with extensive experience across venture capital, biopharmaceutical strategy, and corporate development. He is a co-founder and served for more than a decade as Managing Director of Vatera Healthcare Partners, a family office-based venture capital firm, focused on investments in innovative life sciences and healthcare companies. Mr. Kodiyalam has held senior leadership roles in the biopharmaceutical industry, including Senior Vice President of Commercial Development and New Business Ventures at Kos Pharmaceuticals, where he played a central role in shaping the company’s late-stage pipeline, strategic partnerships, and growth strategy prior to its acquisition by Abbott Laboratories. His earlier career includes commercial and business development leadership positions at Ortec International, Schering-Plough Corporation, and Novartis Pharmaceuticals, with responsibilities spanning global marketing, new product management, licensing, and strategic alliances. In addition to his operating and investment experience, Mr. Kodiyalam has served and continues to serve on the boards of numerous private and public biotechnology and healthcare companies. Mr. Kodiyalam holds a Bachelor of Pharmacy from Madras University in India and a Master of Science in Pharmaceutical Administration from The Ohio State University.

Patrick James Heron, published by Frazier Life Sciences as Patrick Heron, is a managing partner at Frazier Life Sciences and a member of the Gates Foundation Strategic Investment Fund Investment Committee. The foundation publishes his authentic Frazier portrait and current committee affiliation.

Matt is a corporate and transactional attorney with over 25 years of experience negotiating and documenting complex investments. During his 11 years at the foundation he has been the lead transaction counsel on more than 50 completed program-related investments, mission-related investments and other innovative financing transactions involving entities in over a dozen different countries. Prior to joining the foundation, he spent 15 years at K&L Gates LLP where he was a partner in the corporate/securities group. At K&L Gates he represented public and private companies in the full range of corporate and securities law matters, including corporate and limited liability company formations, joint ventures, mergers and acquisitions, public and private securities offerings, compliance with state and federal securities laws, stock exchange listing and corporate governance. He also represented clients in negotiating and drafting prime brokerage documentation, ISDA agreements and futures documentation. He is a graduate of Stanford University and the UCLA School of Law.

Jill manages the coordination of all strategic investments and contracts including data management and analysis. She acts as a primary point of contact for internal and external stakeholders ensuring deliverables and deadlines of portfolio investments are met. Prior to joining the foundation, Jill was an Administrative Assistant at Educational Services of America. Jill earned her B.A. and M.B.A. from the University of North Alabama.

Ken is a corporate and securities attorney who provides strategic advice and practical solutions in connection with the foundation’s program-related investments and other complex transactions, as well as advising on securities compliance matters and general corporate governance.

Susan is a corporate attorney who advises on the foundation’s program-related investments, innovative finance investments and other complex transactions across the foundation. Prior to joining the foundation, Susan was counsel at the United States Development Finance Corporation (DFC) where she specialized in project finance investments in the renewable energy, healthcare, infrastructure and microfinance sectors in Latin America, Africa and Southeast Asia. Susan began her career as a corporate attorney at Cleary Gottlieb Steen & Hamilton LLP in New York City. She graduated magna cum laude from Columbia College, Columbia University and with honors from Columbia Law School.

Logan Morwick Miller joined the Gates Foundation in 2023 and serves as an Associate of the Strategic Investment Fund (SIF). Since joining, Logan has evaluated and structured investments in the biotech, agriculture technology and education technology sectors, as well as volume guarantees supporting new HIV PrEP products. She is the Foundation’s Board Observer for Carnegie Learning and Vedanta Biosciences. Prior to joining the Foundation, Logan worked in the Private Capital division of the Ontario Teachers’ Pension Plan, where she evaluated, executed, and monitored investments in the Diversified Industrials and Business Services sectors. Logan also worked as an Investment Banking Analyst at TD Securities in Toronto. Logan received her BA in Honors Business Administration from the Ivey Business School, at Western University.

Antonio Garcia Maldonado is a Partner at SIF. He works on international investments with a focus on biotech in Europe and Israel, and tech-enabled service/product delivery in South Asia and Sub-Saharan Africa. Prior to joining the foundation, Antonio worked in the investment banking division at JPMorgan. There, he worked on structuring and executing M&A, equity and debt transactions across the Technology and Healthcare industries. Antonio obtained his Bachelors of Laws and Bachelors in Business Administration from ICADE – Universidad Pontificia de Comillas (Madrid, Spain); and his Graduate Diploma in Law and in Human Rights Law from the University of Law and the London School of Economics and Political Science respectively.

Elisabeth joined the Gates Foundation in March 2026 and serves as an Associate of the Strategic Investment Fund (SIF), where she works as a generalist across the Fund’s investment areas. Prior to joining the Foundation, Elisabeth was an Investment Banking Analyst at Morgan Stanley within the Industrials Group in New York City, where she executed buyside, sellside, and IPO transactions across the data center, automotive, and industrial technology sub-sectors. Elisabeth holds a Bachelor’s degree from Columbia University, where she double-majored in Economics and Political Science.

Kristin provides operational support to the Strategic Investment Team. She received a B.S. in hospitality and tourism management from Virginia Tech University focusing on event management. Starting as a contractor for the Gates Foundation five years ago, Kristin joined full-time soon after and has been with the SIF team for three years. Kristin focuses on processing Programmatic Related Investments for the SIF team and the Accelerator team, shepherding new investments from start to finish. She works closely with internal and external partners to ensure all compliance standards are met and that new partners are introduced to foundation practices.

Rutendo joined the Gates Foundation in 2026 and serves as Investment Officer for the Strategic Market Tools initiative within the Strategic Investment Fund (SIF). She partners with program strategy teams to structure, negotiate, and execute complex transactions with private sector entities, multilaterals, and governments, using guarantees and other structured/innovative finance tools to lower the cost of critical health commodities and expand access in the foundation’s priority geographies. Prior to joining the foundation, Rutendo worked in Innovative Finance at the United Nations. Earlier, she was a Vice President in Lazard’s Special Opportunities team, reporting directly to the CEO, where she focused on strategic and sovereign advisory and M&A. She began her career at Bridgewater Associates, where she served as an Investment Associate and went on to be a team lead on the firm’s Onshore China and Portfolio Strategy work. Rutendo holds a BA from the University of Pennsylvania. She also holds a Master of Public Policy and an MBA from the University of Oxford, where she studied as a Rhodes Scholar. A native of Zimbabwe, Rutendo brings strong personal conviction to her work on health and economic opportunity across the developing world.

Jessica joined the Gates Foundation in July 2025 as Senior Coordinator providing operational support to the Strategic Investment team. Prior to joining the Gates Foundation, Jessica built a career spanning more than 20 years in operations, human resources, executive support, and business administration within the biotechnology, pharmaceutical, and investment sectors. She spent over two decades with Accelerator Corporation, where she served in senior operational leadership roles supporting venture creation, portfolio company development, investor relations, and executive operations. During her tenure, she worked closely with leadership teams and helped establish and scale multiple early-stage life sciences companies. Before joining Accelerator, Jessica worked at Prolinx, Inc., a venture-backed biotechnology company focused on technologies supporting drug discovery. There, she managed a broad range of operational and marketing functions supporting the company’s growth and commercialization efforts. Jessica received a Master of Business Administration from Seattle University and a Bachelor of Arts in History from the University of Washington.

Zainab Bakrin is an Associate at the Gates Foundation’s Strategic Investment Fund, focused on the Biotech Accelerator program. Prior to joining the Gates Foundation in 2024, Zainab was a member of the investment team at Casdin Capital, where she focused on life science tools, diagnostics, healthcare IT, and industrial applications of biotechnology. Zainab started her career in investment banking at Goldman Sachs and holds a B.A. in Neuroscience from Dartmouth College. Zainab has lived in Lagos, Nigeria; Johannesburg, South Africa; New York City and is currently based in Seattle. She enjoys playing soccer, cycling, and supporting women’s sports in her spare time.

Vanessa Bhark is a Principal at the Gates Foundation’s $2.5 billion Strategic Investment Fund (SIF), the foundation’s venture capital, debt, and guarantee fund. Prior to joining the Gates Foundation in 2021, Vanessa was a member of the investment team at Frazier Healthcare Partners, focused on biopharmaceuticals. Vanessa has also held positions in corporate and business development at Gilead and J&J, leading the diligence and structuring of partnerships, licenses and acquisitions for novel pharmaceutical technologies. Vanessa started her career in biotech equity research at Morgan Stanley. Vanessa has an M.B.A. from the Kellogg School of Management and a Bachelor of Science in Chemical Engineering from MIT.

While she maintains a diverse portfolio, Julie spends the majority of her time focused on healthcare delivery, which comprises debt, equity, and volume guarantee investments that improve primary healthcare, maternal and child health, and infectious disease. Recognizing that there will never be enough trained medical providers, she focuses on the role that technology-enabled diagnostics, devices, and software can enable doctors, midwives, and community health workers to provide higher-quality care in low- and middle-income countries. Prior to her investment career on the SIF team, Julie was Chief of Staff to the foundation’s CFO. Before joining the foundation in 2008, Julie held finance roles at a publicly traded company and with a microfinance organization in Nicaragua. She began her career in public accounting at KPMG. Julie holds a B.B.A. in Finance and Accounting from Gonzaga University.

Ryan Kreitzer joined the Strategic Investment Fund in 2014. Based in Seattle, Ryan invests across fintech, healthtech, agritech & climate, focusing on innovative companies that develop new solutions to long-standing challenges that impact patients, farmers and consumers globally. He also leads SIF’s investing practice in Sub-Saharan Africa, where he invests in businesses that deliver innovations to those that need them most. He currently serves as the Gates Foundation’s board observer on a number of companies, including Pula Advisors and Enko. Prior to joining the foundation, Ryan worked in investment banking at Evercore. There, he advised on mergers and acquisitions, spin-offs, and strategic transactions involving clients across a variety of industries. Ryan graduated from New York University’s Stern School of Business with a B.S. in Finance and Economics.

David Rossow joined the foundation in 2010 as part of a $400 million pilot to establish the Strategic Investment Fund. He currently heads the fund’s international work with a focus on biotech in Europe, and tech-enabled service & product delivery in South Asia and Sub-Saharan Africa. Prior to joining the foundation in 2010, David worked on deal teams in private equity and investment banking, where he was responsible for executing leveraged buyout, equity, debt, restructuring, and merger & acquisition transactions across a variety of industries. David holds a B.A. in Economics from St. Olaf College.

Natalie Revelle leads the Volume Guarantee initiative and structured financing investments within the SIF team. Working with pharmaceutical companies, sovereign and private foundation partners, donors, and implementing partners, Natalie has structured a portfolio of investments across global health commodities including vaccines, family planning, and HIV products that is expected to generate over $1 billion of procurement savings. Natalie also serves as senior financial advisor to the CFO for complex transactions for achieving impact and as a subject matter expert on how programs can bring about impact through financial tools. Prior to joining the foundation, Natalie held a number of strategy and financial advisory roles. Most recently, Natalie worked at McKinsey & Company where she served high tech clients on strategy development, procurement, and pricing topics. Natalie is a graduate of Harvard Business School and Princeton University with a Bachelor of Arts in Economics.

Thong Q. Le joined the Gates Foundation in December 2024 and serves as Investment Director and Managing Partner of the Strategic Investment Fund (SIF), the Foundation’s impact investment arm. In this role, he leads the use of equity, debt, guarantees, and other investment tools to advance the Foundation’s philanthropic goals. Thong brings more than 25 years of investment and leadership experience across the life sciences industry, with a track record of building companies, making impact-oriented investments, and developing investment strategies designed to improve lives. Prior to joining the Gates Foundation, Thong served as Senior Managing Director and CEO of Accelerator Life Science Partners (ALSP), a venture capital firm focused on creating and developing next-generation life sciences companies. After joining ALSP in 2013, he helped shape the firm’s strategy and led its expansion beyond the Pacific Northwest. He also served as a director and founding President & CEO of more than a dozen ALSP portfolio companies, including Petra Pharma (acquired by a global pharmaceutical company in 2020); Rodeo Therapeutics (acquired by Amgen Inc. for up to $721 million in 2021); and Lodo Therapeutics (acquired by Zymergen in 2021, now Ginko Bioworks). Before joining ALSP, Thong spent nearly 15 years as Managing Director of WRF Capital, the venture investment arm of the Washington Research Foundation, where he invested in and supported the growth of early-stage life sciences and technology companies. Thong received his A.B. in Government from Harvard University and undertook postgraduate studies in business at Templeton College, Oxford University.

As a trustee from 2006 – 2021, Warren Buffett worked along with Bill Gates and Melinda French Gates to help shape our vision and develop strategies to address some of the world's most challenging inequities. Buffett is a U.S. businessman and philanthropist. As chairman and chief executive officer of Berkshire Hathaway Inc., he has invested in a broad range of companies, from See's Candies to Geico Insurance to Fruit of the Loom. Through 2022, Warren’s contributions to the Gates Foundation total $36 billion valued at the time of receipt. Warren attended the Wharton School at the University of Pennsylvania and received his bachelor's degree from the University of Nebraska. In 1951, he earned a master's degree in economics from Columbia University. Warren and his late wife, Susan Thompson Buffett, raised three children: Susie, Howard, and Peter. Now married to Astrid Menks Buffett, Warren lives and works in his hometown of Omaha, Nebraska. The impact of [Warren’s] prodigious generosity is hard to quantify. Even harder to quantify is how his values have permeated the foundation’s culture. - Mark Suzman Chief Executive Officer, Gates Foundation

William H. Gates Sr. d. 2020) guided the vision and strategic direction of the foundation and served as an advocate for the foundation’s key issues. He first answered his son's request for help in using his resources to improve reproductive and child health in the developing world by directing the William H. Gates Foundation, which was established in 1994. It merged with the Gates Learning Foundation to create the Gates Foundation in 2000. Bill Sr. earned his bachelor's and law degrees from the University of Washington, following three years of U.S. Army service in World War II. A founding partner at Preston Gates & Ellis, Bill Sr. served as president of both the Seattle/King County Bar Association and the Washington State Bar Association. He has served as trustee, officer, and volunteer for more than two dozen Northwest organizations, including the Greater Seattle Chamber of Commerce and King County United Way. In 1995, he founded the Technology Alliance, a cooperative regional effort to expand technology-based employment in Washington. Bill Sr. was also a strong advocate for education for many years, chairing the Seattle Public School Levy Campaign in 1971 and serving as a member of the University of Washington's Board of Regents from 1997-2012. Bill Sr. and his first wife, Mary Maxwell Gates (d. 1994), raised three children Kristianne, Bill , and Libby. For many years, he continued his lifelong commitment to many civic programs, cultural organizations, and business initiatives. He passed away on September 14, 2020 and is survived by his second wife, Mimi Gardner Gates, his three children, and eight grandchildren.

Melinda French Gates is a philanthropist, businesswoman, and global advocate for women and girls. She founded and co-chaired the Gates Foundation, where, for more than two decades, she set the direction and priorities of the world’s largest philanthropy. Melinda left the Gates Foundation in June 2024. For over 25 years, Melinda has led efforts to unlock a healthier, more prosperous, more equal future. Today, she heads Pivotal, an organization she formed in 2015 that works to accelerate the pace of progress and advance women’s power and influence in the U.S. and around the world. Pivotal drives impact using high-impact investments, philanthropy, partnerships, and advocacy. Melinda has seen firsthand how empowered women and girls transform families, communities, and countries. In her bestselling book, The Moment of Lift, she introduces readers to women whose stories have inspired her and writes about her own journey to becoming an advocate. Through her imprint, Moment of Lift Books, she amplifies other voices by publishing original nonfiction from visionaries working to unlock a more equal world for women and girls. The second of four children, Melinda grew up in Dallas, Texas. She attended Duke University, where she received a bachelor’s degree in computer science and economics and an MBA. Melinda spent the first decade of her career developing multimedia products at Microsoft before leaving the company to focus on her family and philanthropic work. Melinda has three children—Jenn, Rory, and Phoebe—and lives in Seattle, Washington.

Tom Tierney co-founded The Bridgespan Group , an independent global nonprofit focused on helping philanthropists and nonprofit leaders achieve breakthrough results. Over two decades, his leadership has nurtured Bridgespan’s growth and innovation. He is a recognized thought leader in philanthropy, having collaborated with a wide range of grantmakers on issues ranging from strategy to organization. His aspiration is to help increase the flow and effectiveness of philanthropy in ways that reduce inequities. He has served on the foundation’s board of trustees since January 2022. Prior to launching Bridgespan, Tom served as Bain & Company’s worldwide managing partner, where he successfully led the firm through an aggressive phase of innovation and global expansion. A co-author of two highly respected books, Aligning the Stars , and Give Smart: Philanthropy That Gets Results , he has also advised, served on and/or led numerous boards. Most recently he served as chair of The Nature Conservancy , eBay , and Stanford’s Hoover Institution . He is the longstanding chair of the Harvard Business School’s Social Enterprise Initiative and he co-chairs Bridgespan’s board. Tom was the fifth person to hold the class of 1951 Chair for the Study of Leadership at West Point. In 2016, he was the recipient of HBS’s Alumni Achievement Award. Born in San Francisco, California, Tom received his BA in Economics with highest distinction from the University of California at Davis. Upon graduation, he worked as a field engineer for Bechtel in Algeria. In 1980 he earned an MBA with distinction from the Harvard Business School.

* Minouche is currently on leave of absence from her foundation role. Minouche Shafik is an economist, policymaker, and higher education leader who has spent over three decades in leadership roles across a range of prominent international, national, and academic institutions. Effective September 2025, Minouche has taken a leave of absence from the foundation board, following her appointment as Chief Economic Advisor to U.K. Prime Minister Sir Keir Starmer. Previously, she was president of Columbia University and of the London School of Economics and Political Science (LSE), where she drove academic excellence, improved student experience, and raised substantial philanthropic support. Before that, Minouche served as deputy governor of the Bank of England, where she led work on fighting misconduct in financial markets and managed a balance sheet of around US$600 billion. She served on all of the bank’s policy committees which included the Monetary Policy Committee, the Financial Policy Committee, and the Board of the Prudential Regulatory Authority. Before joining the Bank of England, she was deputy managing director of the International Monetary Fund (IMF), where she navigated the turbulence surrounding the European debt crisis and the Arab Spring and modernized the IMF’s approach to building economic policy capacity in member countries. She was also responsible for the IMF’s US$1 billion administrative budget and US$10 billion pension fund. Before joining the IMF, Minouche served as permanent secretary of the UK government’s Department for International Development (DFID). Her tenure there coincided with DFID being ranked the best-performing department in government, and she helped secure the UK’s commitment to giving 0.7% of GDP to fight poverty in the world’s poorest countries. At age 36, Minouche became the youngest-ever vice president of the World Bank, where she worked on the institution’s first-ever report on the environment, led work on infrastructure and private-sector investment, and advised governments in post-communist Eastern Europe. She led policy work and published books on the prospects for economic progress in the Middle East during the Oslo peace process. Minouche received a B.A. from the University of Massachusetts Amherst, an M.Sc. from LSE, and a D.Phil. from St Antony’s College at Oxford University. She holds a life peerage and is a crossbench member of the House of Lords, received a damehood for services to the global economy, an honorary fellowship of the British Academy and of St Antony’s College at Oxford, and has six honorary doctorates. Her most recent book, What We Owe Each Other: A New Social Contract for a Better Society , has been translated into 12 languages. She has served as deputy chair and a trustee of the British Museum, the Council of the Institute for Fiscal Studies, and a governor of the National Institute of Economic and Social Research. She has been a member of the board of the Gates Foundation since 2022.

Strive T. Masiyiwa is a Zimbabwean based in London and an international business leader. He has served on the foundation’s board of trustees since January 2022. Masiyiwa is the Founder and Executive Chairman of South Africa-based Econet Group and Cassava Technologies and is one of the pioneers of the mobile telecoms industry on the African continent. Masiyiwa has also been involved in the development of Africa’s independent media. In May 2020, Masiyiwa was appointed to serve as an African Union Special Envoy to help coordinate Africa’s private sector efforts to procure medical supplies and fight the spread of COVID-19. As Special Envoy he also heads up the Africa Vaccine Acquisition Task Team. He led a similar private sector initiative to fight Ebola in West Africa in 2014-2015. Masiyiwa is a member of the Giving Pledge. In 1996, he and his wife, Tsitsi, cofounded what is now known as the Higherlife Foundation which has supported the education of over 250,000 orphaned, vulnerable, and gifted children across Africa, as well as health, disaster relief and preparedness, and rural transformation programs. Masiyiwa received a bachelor of engineering degree from the University of Cardiff.